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ABSTRACT OF DISSERTATION

POST-TRANSCRIPTIONAL REGULATION
OF MAMMALIAN HEAT SHOCK FACTORS

Heat shock transcription factors (HSFs) function to regulate the expression of heat
shock proteins (hsps) or molecular chaperones in the cell. Mammalian cells have two
well-characterized HSFs, HSF1 and HSF2. HSF1 functions to regulate the stress-induced
expression of hsps. The function of HSF2 appears to be in regulating hsp expression
during development and differentiation.
In this work, I describe two distinct HSF1 mRNA isoforms (HSF1- α and HSF1- β)
that are generated by alternative splicing of the HSF1 pre-mRNA. The two HSF1 mRNA
isoforms result from the inclusion (HSF1- α), or omission (HSF1- β), of a 66 nucleotide
exon of the HSF1 gene, which encodes a 22 amino acid sequence. These results show
that the levels of the HSF1- α and HSF1- β mRNA isoforms are regulated in a tissuedependent manner, with testis expressing predominantly the HSF1- β isoform while heart
and brain express primarily the HSF1- α isoform.
In addition, I describe two distinct HSF2 mRNA isoforms (HSF2- α and HSF2- β)
that are generated by alternative splicing of the HSF2 pre-mRNA. The two HSF2 mRNA
isoforms result from the inclusion (HSF2- α), or omission (HSF2- β), of a 54 nucleotide

exon of the HSF2 gene, which encodes a 18 amino acid sequence. These results show
that the levels of the HSF2- α and HSF2- β mRNA isoforms are regulated in a tissuedependent manner, with testis and brain expressing predominantly the HSF2- α isoform
while heart, liver, and kidney express primarily the HSF2- β isoform. Furthermore, HSF2
isoform levels are regulated both in a developmental and cell type dependent manner in
the testis. In a reporter assay, HSF2- α is a 2.6-fold better transcriptional activator than
the HSF2- β isoform.
We have demonstrated also that HSF2, but not HSF1 is a substrate for SUMO-1
and SUMO-2 modification in vitro. Consistent with this, we have demonstrated that
HSF2 can interact with a portion of Ubc9, the SUMO-1 conjugating enzyme, in a twohybrid assay. We have also shown that GFP-HSF2 colocalizes with SUMO-1 in discrete
nuclear domain structures in 7% of GFP-HSF2 expressing HeLa cells. Finally, we have
shown that lysine 82 of HSF2 is the primary site of SUMO-1 modification in vitro.

____________________________________

____________________________________

POST-TRANSCRIPTIONAL REGULATION
OF MAMMALIAN HEAT SHOCK FACTORS

By
Michael L. Goodson

____________________________________
Co-Director of Research
____________________________________
Co-Director of Research
____________________________________
Director of Gratudate Studies
____________________________________

RULES FOR THE USE OF DISSERTATIONS

Unpublished dissertations submitted for the Doctor's degree and deposited in the
University of Kentucky Library are as a rule open for inspection, but are to be
used only with due regard to the rights of the authors. Bibliographical references
may be noted, but quotations or summaries of parts may be published only with
the permission of the author, and with the usual scholarly acknowledgments.

Extensive copying or publication of the dissertation in whole or in part also
requires the consent of the Dean of the Graduate School of the University of
Kentucky.

A library that borrows this dissertation for use by its patrons is expected to secure
the signature of each user.

Name

Date

DISSERTATION

Michael L. Goodson

The Graduate School
University of Kentucky
2000

POST-TRANSCRIPTIONAL REGULATION
OF MAMMALIAN HEAT SHOCK FACTORS

____________________________________
DISSERTATION
____________________________________
A dissertation submitted in partial fulfillment of the
Requirements from the degree of Doctor of Philosophy
at the University of Kentucky

By
Michael L. Goodson
Lexington, Kentucky
Co-Director: Dr. Kevin D. Sarge, Associate Professor of Biochemistry
Co-Director: Dr. Salvatore J. Turco, Professor of Biochemistry
Lexington, Kentucky
2000

Acknowledgments
First, I would like to acknowledge the contribution of Dr. Kevin Sarge, my
mentor, by whose efforts, I have learned a great deal about the scientific process.
Needless to say (though I still am saying it), this work could not have happened without
his support. Secondly, I would like to recognize the support of my dissertation
committee: Dr. Sam Turco, Dr. Mark Kindy, Dr. Wendy Katz, and Dr. Brett Spear.
Their advice has been instrumental in my work. I would also like to thank my outside
examiner Dr. Tae Ji, for his comments on my dissertation during the thesis defense
process.
I would also very much like to acknowledge our department’s graduate secretary,
Carol Fowler. Every biochemistry graduate student reaps the benefits of Carol’s tireless
efforts to make to graduate process as pleasant as possible. When she retires next month
she will be sorely missed.
Also, I would like to acknowledge our collaborators. Dr. Michael Matunis
performed all of the SUMO-1 in vitro modification assays. In addition, he provided
many plasmids, the SUMO-1 antibody, and a great deal of SUMO-1 expertise. Without
his help, Chapter 3 of this dissertation would not have been possible. Dr. Joana Desterro
and Dr. Ronald Hay provided several SUMO-1 plasmids, including the GST-SUMO-1
expression plasmid. Dr. Yongho In and Dr. Okkyong Park-Sarge provided the Ubc9
yeast two hybrid plasmid and initially discovered the Ubc9/HSF2 interaction. Finally,
Dr. Sindey Whiteheart provided expertise with immunofluorescent microscopy, as well
as the microscope. Thanks, Wally.

iii

Finally, I would like to thank my family. My parents have always been
supportive of my education. I’m still not leaving college, Mom. Most of all, however, I
would like to thank God from whom all of life’s blessings flow, and to thank my wife
Brenda, the greatest of all blessings. She has been both a great scientist and a great
friend. To this work she has contributed innumerable ideas as well as editorial
comments. She has also always been my solace throughout this process. Brenda, you are
my colleague, my friend, my bulwark, my lover, my soul mate. You give my life
meaning. I love you, and I dedicate this work to you.

And, because every dissertation should have a little Latin in it. . .

"Probae esti in segetem sunt deteriorem datae fruges, tamen ipsae suaptae enitent."
-- Accius, Atreus

iv

Table of Contents
Acknowledgments............................................................................................................... iii
List of Tables ..................................................................................................................... vii
List of Figures ................................................................................................................... viii
Chapter 1 Background and Introduction ......................................................................... 1
Transcription factors, regulators of eukaryotic RNA synthesis ...................................... 1
RNA splicing—removing garbage or creating diversity? .............................................. 4
The cellular stress response........................................................................................... 12
Spermatogenesis, the process of germ cell maturation................................................. 18
Chapter 2 Alternative Splicing Isoforms of HSF1 and HSF2 ........................................ 29
Introduction................................................................................................................... 29
Materials and Methods.................................................................................................. 39
Experimental Animals ............................................................................................... 39
RT-PCR Analysis...................................................................................................... 39
Isolation and Cloning of HSF1 cDNA and Genomic DNA Sequences .................... 41
Western Blot (Immunoblot) and Gel Mobility Shift Analysis.................................. 42
HSF2 Transfection of NIH 3T3 Cells and Luciferase Assays .................................. 42
Results ........................................................................................................................... 43
Tissue distribution of HSF1 mRNA isoforms. ......................................................... 43
Tissue distribution of HSF2 mRNA isoforms. ......................................................... 44
Cloning of HSF1 cDNA isoforms............................................................................. 45
Cloning of HSF2 cDNA isoforms............................................................................. 46
Cloning of the HSF1 genomic DNA from the splice variant region. ....................... 46
HSF1-α splicing creates a fifth potential leucine zipper. ......................................... 47
Cloning of the HSF2 genomic DNA from the splice variant region. ....................... 48
Developmental Regulation of HSF2 mRNA Splicing. ............................................. 49
Increased transcriptional activity of the HSF2-α isoform. ....................................... 49
Discussion..................................................................................................................... 75
HSF1 alternative splicing—implications for differential stress response activation. 75
HSF2 alternative splicing—implications for spermatogenic gene regulation. ......... 76
Chapter 3 SUMO-1 Modification of HSF2 .................................................................... 79
Introduction................................................................................................................... 79
Materials and Methods.................................................................................................. 93
Plasmid DNA Construction ...................................................................................... 93
SUMO-1 Consensus Site Pattern Matching.............................................................. 94
Site Directed Mutagenesis of HSF2.......................................................................... 95
Yeast Transformation and the Two-Hybrid Assay. .................................................. 95
In vitro SUMO-1 Modification Assay...................................................................... 97
Recombinant Protein Expression.............................................................................. 97
Recombinant Protein Purification............................................................................. 98
v

Transient Transfection of HeLa Cells ..................................................................... 100
Immunofluorescent Microscopy............................................................................. 101
Results ......................................................................................................................... 102
Two Hybrid Analysis of the HSF2/Ubc9 interaction ............................................. 102
In vitro SUMO-1 modification of HSF2................................................................. 106
Nuclear colocalization of SUMO-1 and GFP-HSF2. ............................................. 108
Identification of the SUMO-1 modification site in HSF2. ..................................... 110
Discussion................................................................................................................... 130
Chapter 4 Discussion and Future Directions............................................................... 132
The functional difference between HSF1-α and HSF1-β........................................... 132
The possibility of stress induced SUMO modification of HSF1. ............................... 133
The role of HSF2-α and HSF2-β in spermatogenesis. ............................................... 134
Other functions of HSF2 ............................................................................................. 134
The regulation of the SUMO-1 modification of HSF2. .............................................. 135
The 26S proteosome and SUMO modification of HSF2. ........................................... 136
Appendix......................................................................................................................... 138
Appendix A: List of Abbreviations ............................................................................ 138
References ....................................................................................................................... 139
Vitae ................................................................................................................................ 152

vi

List of Tables
Table 1. Quantification of GFP-HSF2 nuclear domain staining ............................. 110

vii

List of Figures
Figure 1.1: Schematic representation of the RNA splicing reaction. ................................ 7
Figure 1.2: Schematic representation of alternative splicing. .......................................... 11
Figure 1.3: Schematic diagram of the cellular stress response. ....................................... 15
Figure 1.4: Schematic diagram of spermatogenesis. ....................................................... 22
Figure 1.5: Diagram of one cycle of spermatogenic stages. ............................................ 27
Figure 2.1: Human and mouse HSF DNA and protein sequence alignments.................. 31
Figure 2.2: RT-PCR analysis of HSF1 mRNA isoforms in mouse tissues...................... 52
Figure 2.3: Western blot analysis of HSF2 protein from mouse tissues........................... 54
Figure 2.4: RT-PCR analysis of HSF2 mRNA isoforms in mouse tissues....................... 56
Figure 2.5: Nucleotide and deduced amino acid sequences of HSF1 mRNA isoform
cDNAs....................................................................................................................... 58
Figure 2.6: Nucleotide and deduced amino acid sequences of HSF2 mRNA isoform
cDNAs....................................................................................................................... 60
Figure 2.7: Sequence of HSF1 gene regions corresponding to alternative splice junctions.
................................................................................................................................... 62
Figure 2.8: Schematic representation of HSF1 mRNA alternative splicing. .................... 64
Figure 2.9: Novel leucine zipper motif in HSF1-α.......................................................... 66
Figure 2.10: Sequence of HSF2 gene regions corresponding to alternative splice
junctions. ................................................................................................................... 68
Figure 2.11: Schematic representation of HSF2 mRNA alternative splicing. .................. 70
Figure 2.12: RT-PCR analysis of HSF2 isoforms during testis development. ................ 72
Figure 2.13: Reporter gene analysis of HSF2-α and HSF2-β isoforms. ......................... 74
Figure 3.1: Schematic representation of the ubiquitination cycle..................................... 81
Figure 3.2: Schematic representation of the SUMO-1 modification cycle....................... 86
Figure 3.3: Schematic diagram of the yeast two hybrid assay. ....................................... 105
Figure 3.4: Two-hybrid analysis of the HSF2/Ubc9 interaction. .................................... 113
Figure 3.5: In vitro SUMO-1 and SUMO-2 modification of HSF2. ............................. 115
Figure 3.6: In vitro SUMO-1 modification analysis of HSF1. ...................................... 117
Figure 3.7: Colocalization of GSP-HSF2 and SUMO-1................................................ 119
Figure 3.8: Unique localization of GFP-HSF2. ............................................................. 121
Figure 3.9: Purification of recombinant HSF1 and SUMO-1......................................... 123
Figure 3.10: Preadsorbed control for SUMO-1 Immunofluorescent Staining............... 125
Figure 3.11: Consensus SUMO-1 modification site analysis of HSF2. ........................ 127
Figure 3.12: In vitro modification analysis of HSF2 mutants. ...................................... 129

viii

Chapter 1
Background and Introduction

TRANSCRIPTION FACTORS, REGULATORS OF EUKARYOTIC RNA SYNTHESIS

Each cell in a multicellular organism has DNA with exactly the same sequence as
every other cell in that organism, yet the cells of that organism are highly diverse both in
function and morphology. With only a few small exceptions, such as gene rearrangement
in immune cells, germ cells, transposons, and random mutations, this is true for every
metazoan. How then does an organism generate this cellular diversity from identical
genetic material? The answer to this lies in the pattern of gene expression. Different
cells express different genes at different levels. Therefore, an organism must carefully
regulate the expression of its genes. One major mechanism for controlling gene
expression is by regulating transcription of DNA into RNA (Maniatis et al., 1987).
Eukaryotic genes are transcribed by one of three RNA polymerases. RNA
polymerase I transcribes ribosomal RNA. RNA polymerase III transcribes small RNA
molecules such as the 5S ribosomal RNA and transfer RNA. RNA polymerase II
transcribes RNA from genes that will be translated into protein, called messenger RNA
(Chambon, 1975; Geiduschek and Tocchini-Valentini, 1988; Sentenac, 1985; SollnerWebb and Tower, 1986). In eukaryotes, RNA polymerases are large multi-subunit
protein complexes with masses of 500 kDa or more. Unlike in prokaryotes and viruses,
the eukaryotic RNA polymerases do not directly recognize DNA sequences. Rather
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DNA binding proteins, called transcription factors, bind to specific sequences in the
promoter regions of genes and thereby recruit the RNA polymerase complexes (Brown,
1984; Workman and Roeder, 1987).
Promoter regions are transcriptional regulatory sequences of genes that can be
divided into two categories proximal promoter elements and distal enhancer elements.
The basal promoter elements contain sequences such as GAGA elements, the TATA box,
or the initiator (Inr) motif. Basal promoter elements are highly context sensitive and
must be located near the transcription start site (Atchison, 1988; Maniatis et al., 1987;
McKnight and Kingsbury, 1982). For example, in genes that contain one, the TATA box
is always located approximately 30 bp upstream of the start site. In contrast, enhancer
elements are often found several kb upstream of the transcription start site. They can also
be found several kilobases upstream of the gene, downstream of the gene, or within the
transcribed region of the gene. Enhancer regions usually contain binding sites for
multiple regulatory proteins and are normally modular. This modular quality means that
enhancers can often be moved to different locations within the promoter region of a gene,
or within the context of a completely different basal promoter and gene (as in the case of
a reporter gene assay) (Atchison, 1988; Emerson et al., 1987; Evans et al., 1988; Jones et
al., 1988; Nomiyama et al., 1987).
Similarly transcription factors can be divided into two categories: i) general
transcription factors, which bind to basal promoter elements in nearly all genes and to the
RNA polymerase complex, and ii) transcription enhancers and repressors which bind to
enhancer elements. For the purpose of this introduction, I will specifically refer to
general transcription factors and will often refer to transcription enhancers and repressors
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as transcription factors. All three RNA polymerases have general transcription factors
(TFI, TFII, and TFIII) for binding to promoters and regulating transcription of their
respective genes. In this introduction, I will limit discussion to RNA polymerase II
transcription factors.
General transcription factors bind to the basal promoter region of most genes
forming a stable complex on the DNA and recruiting the RNA polymerase. Examples of
general transcription factors include TFIIA, TFIIB, TFIID (which includes the TATA
binding protein, TBP), TFIIE, and TFIIH and GAGA factors (Burley and Roeder, 1996;
Orphanides et al., 1996; Roeder, 1996). These factors are expressed in all tissues, and
therefore cannot account for the diverse patterns of gene expression found in the body.
Transcription enhancers and repressors, which bind to sequences in the enhancer
region, are much more diverse in composition, function, and expression than the general
transcription factors. Heat shock factors (HSFs) are considered transcription enhancers.
Transcription enhancers (or repressors) bind to DNA and modulate transcription by
several mechanisms. Some function by bending DNA and changing the proximity to
other elements (Ogbourne and Antalis, 1998). Others function by interacting with the
general transcription factors or the RNA polymerase and modulating the function of these
components. Still others interact with other transcription enhancers or repressors to
modulate an effect synergistically (Evans, 1988; Schulman et al., 1995). Transcription
enhancers and repressors are particularly interesting because they are often functionally
regulated (Verrijzer and Tjian, 1996). Regulation of transcription factors may occur by
regulation of transcription factor expression, by interaction with a cellular factor or
ligand, as in the steroid hormone receptors, or by modification by a receptor or receptor
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mediated signal transduction cascade, as in STATs, fos, or jun. To this already complex
paradigm of multiple transcription factors, each regulated in its own unique fashion, we
can add that most transcription factors bind as multimers (Ap-1, RXR, T3R, VDR). The
composition of these multimeric transcription factor complexes often dictates DNA
binding specificity and the functional consequence of binding—whether the complex
activates or represses transcription (Evans, 1988; Umesono and Evans, 1989; Umesono et
al., 1991). Also, many transcription factors interact in a regulated fashion with other
cellular factors that can modulate transcriptional activity. Such layers of regulation can
create the tremendous diversity of gene expression necessary for a multicellular organism
(Chen, 1999).

RNA SPLICING—REMOVING GARBAGE OR CREATING DIVERSITY?

As described previously, eukaryotic genes are transcribed by one of three RNA
polymerases. Of these, only RNA polymerase II transcribes genes that will be translated
into proteins. The mRNA transcribed from RNA polymerase II is modified at the 5’ end
by the addition of a unique cap structure—7-methyl-guanosine in a 5’ to 5’ triphosphate
linkage—called the 5’ cap (Shatkin, 1987). The 3’ end of the RNA is also modified by
the addition of a series of non-encoded adenosine residues called the poly-A tail. Only
messenger RNA contains a 5’ cap and a ploy-A tail (Sisodia et al., 1987; Smale and
Tjian, 1985).
In addition to 5’capping and poly-A tailing, eukaryotic mRNA, particularly
mRNA from metazoans, requires further processing. The genes encoding proteins in
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higher eukaryotes contain both coding sequences referred to as exons and intervening
sequences referred to as introns. The process of removing the introns in pre-mRNA and
joining the exons to form mature mRNA is called RNA splicing (Chambon, 1981; Crick,
1979; Perry, 1981). A large macromolecular complex called the spliceosome, which
contains four small nuclear ribonuceoproteins (snRNPs) U1, U2, U5, and U4/U6, usually
carries out the splicing reaction (Figure 1.1) (Dreyfuss et al., 1988; Guthrie and Patterson,
1988; Osheim et al., 1985; Samarina et al., 1966; Steitz, 1988).
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Figure 1.1: Schematic representation of the RNA splicing reaction.

U1 and U2 snRNPs bind to the 5’ donor and branch point adenosine sites within the
intron of a pre-mRNA, causing assembly of the spliceosome and bendingof the premRNA. Reciprocal nucleophilic attacks by the branch point adenosine and then the 5’
donor site result in the joining of the exonic sequences and liberation of the intron as a
branched lariat structure. Figure adapted from Molecular Biology of the Cell 2nd ed.
(Alberts et al., 1989).
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Figure 1.1: Schemat ic representation of the RNA splicing reaction.
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The U1 snRNP binds to the 5’ donor site at the 5’ end of an intron. The U2 snRNP binds
to an adenosine residue near the 3’ end of the exon called the branchpoint adenosine.
The U5 and the U4/U6 snRNPs then assemble around the other two snRNPs to form the
spliceosome complex, which holds the pre-mRNA in an appropriate conformation to
allow the splicing reactions to occur. The first splicing reaction is a nucleophilic attack
on the phosphoester bond of the 5’ donor site by the 2’ hydroxyl group of the branchpoint
adenosine. This reaction leaves a free 3’ hydroxyl group on the 5’ donor site and creates
a branched 5’-3’ and 5’-2’ phosphodiester bonded structure on the branchpoint adenosine
called a lariat structure. The second splicing reaction is a nucleophilic attack on the
phosphoester bond of the 3’ acceptor site by the 3’ hydroxyl group of the 5’ donor site.
This reaction joins the 5’ donor site to the 3’ acceptor site in a phosphodiester bond
excising the intron as a free lariat structure (Edmonds, 1987; Maniatis and Reed, 1987;
Padgett et al., 1986; Reed and Maniatis, 1988; Rio, 1992b). Both the 5’ donor site and 3’
acceptor sites have consensus sequences that are recognized by the spliceosome and help
to confer specificity on the splicing reaction. The consensus sequence for the 5’ donor
site is 5’-C/A A G * G U A/G A G U.-3’ and the 3’ acceptor consensus sequence is 5’(U/C)n N C/U A G * G/A-3’ (where the G U and A G are nearly invariant residues, N is
any nucleotide, n is number usually greater that 10, and * represents the boundary
between exonic and intronic sequences).
The spliceosome appears to function by binding to the pre-mRNA and holding it
in a conformation that favors the splicing reaction. Evidence for this comes from mRNA
molecules that can automatically carry out the splicing reactions in the absence of the
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spliceosome snRNPs or other protein factors. These mRNA molecules contain regions
that are called self-splicing introns. There are two classes of autocatalytic introns
referred to as Group I and Group II self-splicing introns, which differ subtly in the
splicing reaction mechanism. Group II self-splicing exons carry out chemical reactions
identical to those observed for spliceosome mediated RNA splicing. Thus the
spliceosome likely evolved from self splicing RNA (Cech, 1986).
The spliceosome is capable of catalyzing the excision of an intron between any 5’
donor site and any other 3’ acceptor site, even between to separate RNA molecules.
Thus, the issue of specificity, as mammalian genes often have a number of introns and
exons, is an important question. Failure to appropriately splice the exonic sequences
together could easily result in a nonfunctional protein. The consensus sequence
addresses the issue of exactness in excision nucleotide selection (Padgett et al., 1986;
Rio, 1992b). One likely explanation for the accuracy in overall splice site selection is
that splicing occurs simultaneously with transcription. Thus, adjacent splice sites would
usually be selected because they would have been synthesized at approximately the same
time, thereby removing many of the other choices in possible splice sites. Visualization
of the spliceosomes on the elongating mRNA by electron microscopy supports this
mechanism (Osheim et al., 1985).
Often in eukaryotes pre-mRNA from a single gene may be spliced in multiple
patterns (Rio, 1992a). This alternative splicing can occur from the use of alternative
5’donor sites, alternative 3’ acceptor sites, or the inclusion or exclusion of entire exons,
called exon skipping (Figure 1.2).
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Figure 1.2: Schematic representation of alternative splicing.

Alternative splicing can arise from the use of alternative 5’ donor sites, alternative 3’
acceptor sites, or the inclusion or omission of entire exons. The gray lines represent
alternatively spliced regions of mRNA and the thin bent lines represent joined regions of
the RNA molecule.
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Figure 1.2: Schematic representation of alternative splicing.
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This alternative splicing often occurs in a tissue dependent or other regulated manner.
Alternative RNA splicing presumably functions to provide even greater genetic diversity
to an organism. Multiple proteins with differing functions can be made from a single
gene.

THE CELLULAR STRESS RESPONSE.

One fundamental requirement of all cells from bacteria to humans is the ability to
respond and adapt to stresses. Stress comes in a wide variety of forms from
environmental toxins, pathogens, metabolic products, to simple increases in temperature.
In order for cells and organisms to remain viable, they must have mechanisms for sensing
and responding to these conditions.
One of the common deleterious effects of all of these stresses is protein
denaturation. Therefore, organisms express a family of proteins called heat shock
proteins (hsps) or molecular chaperones, which bind to malfolded proteins allowing them
to refold to their native structure. Hsps accomplish this by repeatedly binding and
releasing stretches of hydrophobic amino acids in malfolded proteins (Becker and Craig,
1994; Craig, 1993; Craig et al., 1993; Gilbert, 1994; Hendrick and Hartl, 1993; Hendrick
and Hartl, 1995). By binding these hydrophobic stretches, hsps are thought to function to
prevent malfolded proteins from becoming aggregating, a situation that requires the
degradation of the protein aggregates (Craig et al., 1994).
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Eukaryotic cells express a number of different classes of hsps. Certain hsp family
members (hsc70 and hsp90) are expressed constitutively in order to assist with de novo
protein folding (Freeman and Morimoto, 1996). Other family members (BiP and mt
hsp70) are expressed in specific organelles such as the endoplasmic reticulum and
mitochondria to assist with protein translocation and folding in these organelles
(Bhattacharyya et al., 1995; Pfanner et al., 1994; Stuart et al., 1994). The expression of
other hsps, such as hsp70, is upregulated in response to cellular stress. These stressinduced hsps were the first identified, and still receive a great deal of study (Schiller et
al., 1988).
A family of transcription factors called heat shock factors (HSFs) controls the
stress-induced upregulation of hsp gene expression in eukaryotic cells. In metazoan cells,
HSFs function by sensing stress, trimerizing, translocating to the nucleus, and binding to
DNA to activate transcription. HSFs bind to promoters that contain a heat shock element
(HSE), inverted repeats of the DNA sequence NGAAN (Amin et al., 1988; Amin et al.,
1994; Morimoto, 1998; Mosser et al., 1988; Perisic et al., 1989). Heat shock protein
genes are among the genes that contain HSEs in their promoters (Figure 1.3).
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Figure 1.3: Schematic diagram of the cellular stress response.

Stressful conditions such as heat shock, heavy metals, oxidative stress, or ischemia, or
conditions such as early embryonic development act on the cell to activate HSF1.
Develomental and differentiation states such as spermatogenesis influence the cell and
cause the activation of HSF2. During late embryogenesis, both HSF1 and HSF2 are
activated. Activation of HSF results in its trimerization, nuclear localization, acquisition
of DNA binding, and activation of transcription. HSF activation results ultimately in the
upregulation of hsps, which provides a cytoprotective function through protein
chaperoning activity.
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Figure 1.3: Schematic diagram of the cellular stress response.
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How heat shock factors sense stress is still unclear. One popular hypothesis is
that heat shock factors can directly sense denatured proteins in the cell. This model
explains how a wide variety of compounds and stresses could activate HSFs. This model
also explains the observation that an HSF from the same organism can have different
activation temperatures in different tissues or when ectopically expressed in a different
organism (Brown, 1995; Voellmy, 1996).
In mammalian cells there are at least four HSF genes with multiple alternative
mRNA splicing isoforms arising from at least two of the HSFs (Nakai et al., 1995; Nakai
et al., 1997; Rabindran et al., 1991; Sarge et al., 1991; Schuetz et al., 1991). The best
characterized of these are HSF1 and HSF2. HSF1 is the HSF that is responsible for
sensing stress and activating expression of hsp genes as described previously (Morimoto
et al., 1992). HSF2, on the other hand, has traditionally been thought to regulate hsp
genes during development and differentiation, although the data for this are not as strong
as for the role of HSF1 (Alastalo et al., 1998; Mezger et al., 1994; Murphy et al., 1994;
Pirkkala et al., 1999; Sarge et al., 1994; Sistonen et al., 1992). Recently, HSF2 has also
been shown to interact with a regulatory subunit of protein phosphatase 2A (PP2A),
suggesting that it may also have a role in regulating phosphatase activity in the cell
(Hong and Sarge, 1999). So, to date, the role (or roles) for HSF2 in the cell remains
unclear.
The cellular function of HSF1 has been well characterized. HSF1 exists as a
phosphorylated non-DNA binding monomer in unstressed cells. Upon exposure to stress,
HSF1 trimerizes, becomes hyperphosphorylated, translocates to the nucleus, binds to
specific DNA elements called HSEs, and activates transcription (Baler et al., 1993; Sarge
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et al., 1993; Westwood and Wu, 1993). Many stressful stimuli that activate HSF1 have
been characterized. Chemical and environmental stresses such as heavy metals, amino
acid analogs, metabolic inhibitors, and elevated temperature all activate HSF1. In
addition, certain pathophysiological conditions such as fever, inflammation, ischemia,
and oxidative damage also activate HSF1 (Morano and Thiele, 1999; Morimoto et al.,
1996).
HSF1 does not require phosphorylation for activity, but phosphorylation does
modulate its activity. Phosphorylation in the basal inactive state at Ser 303 and Ser 307
represses transcriptional activity (Chu et al., 1996; Farkas et al., 1998; Kim et al., 1997;
Kline and Morimoto, 1997; Knauf et al., 1996; Mivechi and Giaccia, 1995; Shi et al.,
1995). Activation of HSF1 produces changes in phosphorylation pattern. The active
state phosphorylation functions to increase the transcriptional activity of HSF1 (Cotto et
al., 1996; Xia et al., 1998; Xia and Voellmy, 1997). Not all stimuli that activate HSF1
DNA binding also induce hyperphosphorylation (Cullen and Sarge, 1997; Jurivich et al.,
1995). Activation by these stimuli is associated with lower levels of transcriptional
activity. Sodium salicylate, for example, activates HSF1 DNA binding, but does induce
that hyperphosphorylation observed with heat, and appears to actually inhibit HSF1 from
activating transcription (Giardina and Lis, 1995; Jurivich et al., 1995; Jurivich et al.,
1992).
HSF2 mRNA and protein is expressed in every tissue examined. Regulation of
HSF2 occurs during development and differentiation. Both mRNA and protein
expression are tightly regulated during spermatogenesis. HSF2 mRNA is expressed at
very high levels in pachytene spermatocytes and round spermatids (Alastalo et al., 1998;
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Sarge et al., 1994). HSF2 mRNA levels are undetectable in early spermatogenic stages
(spermatogonia and leptotene spermatocytes) and in later stages of spermatogenesis
(elongated spermatids and mature spermatozoa). Consistent with this, germ cell
expressed mRNA only begins to appear twenty-one days postpartum, coincident with
onset of spermatogenesis (Sarge et al., 1994).
HSF2 activation appears to be coincident with HSF2 protein level. In tissues
where HSF2 is expressed at high levels (brain and testis) HSF2 appears to be active
((Sarge et al., 1994); data not shown). In most situations, HSF2 activity does not appear
to be inducible in the same sense as HSF1. The only exception to this is in the
immortalized erythroid cell line K562 in which treatment with hemin causes K562 cells
to differentiate into erythrocytes and causes HSF2 activation (Pirkkala et al., 1999;
Sistonen et al., 1992; Theodorakis et al., 1989). However, K562 cells are the only cells
that exhibit HSF2 activation by hemin treatment. Treatment of K562 cells with hemin
also causes an increase in HSF2 protein levels. Recently, HSF2 has also been shown to
be activated by drugs that block 26S proteosome function, causing and increase in HSF2
protein levels. These observations are consistent with the model that HSF2 activity is
regulated by protein level (Mathew et al., 1998).

SPERMATOGENESIS, THE PROCESS OF GERM CELL MATURATION

Spermatogenesis is the process of formation for male gametes or germ cells. The
entire process of spermatogenesis occurs the testis. The testis is organized into two
compartments, the interstitium and the seminiferous tubules (Russell et al., 1990). The
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interstitial compartment contains blood vessels, testicular macrophages, lymphatic ducts,
and Leydig cells. The purpose of the interstitial compartment is to provide the circulatory
architecture required to provide nutrients and other required factors to the developing
germ cells in the seminiferous tubules (Russell et al., 1990).
The seminiferous tubules are convoluted tubules that contain the developing germ
cells. Each tubule is connected at each end to the effluent duct, the rete testis, by a short
straight tubule (Clermont and Huckins, 1961). While each seminiferous tubule is highly
convoluted, the tubule runs primarily longitudinally through the testis, allowing for cross
sectioning of the tubules through the testis. The actually tubule is comprised of collagen
layers bracketing two basement membranes which are separated by myoid cells. Within
the tubule, there are germ cells and nurse cells called Sertoli cells (Clermont, 1958; Dym
and Fawcett, 1970). As the developing sperm cells do not come into contact with the
lymph or blood system, they must receive all of the nutrients and growth factors they
need for development from the Sertoli cells (Clermont, 1958; Dym and Fawcett, 1970).
Spermatogenesis, or the process of maturation of spermatozoa from proliferative
progenitor cells, can be divided into three overall phases. The proliferative phase, or
spermatogonia, the meiotic phase, or spermatocytes, and the differentiation phase, or
spermatids. Mammals are required to produce millions of mature sperm cells every day.
This necessitates continuous production of large numbers of germ cells, which is the role
of spermatogonia (Russell et al., 1990). Spermatogonia can be further subdivided into
three classes, stem cells, proliferative cells, and differentiating cells. The stem cell
spermatogonia are referred to as type Aisolated (Ais) spermatogonia, and are the most
primitive of the germ cell types (Huckins, 1971). Ais are the most insult resistant germ
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cell type due to their relatively infrequent division. For this reason, Ais spermatogonia
often survive when other germ cells are killed off, leading to temporary infertility, and
why complete loss of Ais spermatogonia would result in irreversible infertility (Dym and
Clermont, 1970; Huckins and Oakberg, 1978). Ais divide to regenerate Ais cells and to
form Apaired (Apr) spermatogonia, the first of the two proliferative spermatogonial cell
types (Figure 1.4).
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Figure 1.4: Schematic diagram of spermatogenesis.

Germ cells develop from a single self-regenerating stem cell (a type Aisolated
spermatogonia) into mature spermatozoa through a series of mitotic and meiotic (M-I and
M-II) divisions and differentiation steps. Spermatogonia are the proliferative germ cells,
spermatocytes are the meiotic germ cells, and spermatids are the differentiating germ
cells. Branched arrows represent a cell division. Straight arrows represent a
differentiation step. See text for a description of cell type abbreviations. Figure adapted
from Histological and Histopathological Evaluation of the Testis (Russell et al., 1990)
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Figure 1.4: Schematic diagram of spermatogenesis.
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Apr divide to form Aaligned (Aal) spermatogonia. The terms paired and aligned refer to their
connections to other spermatogonia through intercellular bridges, open cytoplasmic
junctions that connect germ cells and are thought to promote synchronous growth of
spermatogonia and other germ cell types (Weber and Russell, 1987). Aal divide to form
more Aal cells (Huckins, 1978a; Huckins, 1978b; Roosen-Runge, 1973). Though the
signal is not known, when a sufficient number of Aal spermatogonia are generated, they
differentiate in mass to the first differentiating type of spermatogonia, A1 . A1
spermatogonia then divide three more times, forming A2 , A3 and A4 spermatogonia. A4
spermatogonia divide to form intermediate (Int) spermatogonia, which then divide to
form type B spermatogonia (Huckins and Oakberg, 1978). A, Int, and B spermatogonia
differ morphologically by the amount of chromatin, or packaged chromosomal DNA,
located near the inner face of the nuclear envelope. Type A have almost no chromatin at
the periphery of the nucleus, while Type Int and B spermatogonia have progressively
more. Spermatogonia reside at the basal membrane of the seminiferous tubule. They
have a flat surface that is in contact with the wall of the tubule and a rounded surface that
is in contact with the Sertoli cell (Russell, 1977).
Type B spermatogonia divide and differentiate into preleptotene (PL)
spermatocytes, the first of the primary spermatocyte lineages. This is the first of the
meiotic cell types. PL are the last germ cell type to undergo S-phase (DNA replication)
(Moses, 1969; Russell and Frank, 1978). PL differentiate to form leptotene (L)
spermatocytes. L can be distinguished from PL mostly on the basis of morphology. L
spermatocytes begin to round up, detach from the wall, and migrate away from the basal
lamina of the seminiferous tubule. L spermatocytes loose their peripheral chromatin and
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begin forming chromosomal threads, but chromosomes are not yet paired (Russell, 1977;
Russell, 1978). L differentiate into zygotene (Z) spermatocytes as their chromosomes
begin to pair (Moses, 1969). When homologous chromosomes have paired, Z
spermatocytes have differentiated into pachytene (P) spermatocytes. Germ cells remain
as P spermatocytes for a very long time. The prophase of meiosis lasts approximately
three weeks, and of that time, germ cells are P spermatocytes for 1.5 –2 weeks. During
this phase genetic recombination, or crossing over, occurs. During the last half of the P
spermatocyte development, cells become highly synthetic, producing the large amount of
cytosolic and nuclear components required for meiosis, and increase greatly in volume
(Monesi, 1965; Russell and Frank, 1978). As P spermatocytes differentiate to form
diplotene (D) spermatocytes, the chromosomes have separated except at regions called
chiasmata. While D spermatocytes, the cells undergo the metaphase, anaphase, and
telophase of the first meiotic division (MI) (Russell and Frank, 1978). Once the cells
have divided, they are referred to as secondary (2º) spermatocytes. The second meiotic
division (MII) follows rapidly to form spermatids, and the meiotic phase of
spermatogenesis is completed (Russell and Frank, 1978).
The process of differentiation from the immature postmeiotic germ cells to mature
spermatozoa is referred to as spermiogenesis and occurs through approximately nineteen
morphologically distinct phases (Russell et al., 1990). During spermiogenesis the round
spermatids produced from meiosis begin to elongate with the formation of a flagellum.
The elongated spermatids then compact their chromosomal DNA and reduce their size by
75% by eliminating water from the cytosol and nucleus and by eliminating cytosol
through tubular complexes. Finally the sperm cell reduces its volume by releasing a

25
residual body when the mature sperm cell is released from the Sertoli cell into the lumen
of the seminiferous tubule and is excreted (Russell et al., 1990).
The process of spermatogenesis is highly synchronized and proceeds cyclically
through the seminiferous tubule. When tubules are cross-sectioned only certain types of
germ cells are found together in a given region of the seminiferous tubule. In mice, the
spermatogenic process can therefore be divided into 12 stages based on which cell types
are found together in sections of the seminiferous tubule (Figure 1.5) (Leblond and
Clermont, 1952; Oakberg, 1956).
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Figure 1.5: Diagram of o ne cycle of spermatogenic stages.

Spermatogenic development is highly synchronized with only certain types of germ cells
found together in the seminiferous tubule (called stages). The stages are also ordered
with respect to each other within the tubes. Spermatogenesis proceeds through the
seminiferous tubule like a wave in a temporally cyclic fashion. Figure adapted from
Histological and Histopathological Evaluation of the Testis (Russell et al., 1990).
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Figure 1.5: Diagram of one cyc le of spermatogenic stages.
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For example, in stage V, only type B spermatogonia, pachytene spermatocytes, Type 5
round spermatids and type 15 elongated spermatocytes are found. In contrast, at stage X,
only leptotene and pachytene spermatocytes and type 10 early elongating spermatids are
found. One never finds, for example, zygotene spermatocytes and round spermatids
together in the same region of a seminiferous tubule (Russell et al., 1990).

Chapter 2
Alternative Splicing Isoforms of HSF1 and HSF2

INTRODUCTION

As described previously, heat shock transcription factors (HSFs) function to
regulate the expression of heat shock proteins (hsps) or molecular chaperones in the cell
(Craig et al., 1993; Hendrick and Hartl, 1995; Morimoto et al., 1996). Mammalian cells
have two well-characterized HSFs, HSF1 and HSF2 (Clos et al., 1990; Rabindran et al.,
1991; Sarge et al., 1991; Schuetz et al., 1991). HSF1 is ubiquitously expressed in all cell
types examined and functions to regulate the stress-induced expression of hsps. HSF2 is
also ubiquitously expressed in cells, though levels vary widely among cell types. The
function of HSF2 appears to be in regulating hsp expression during development and
differentiation (Alastalo et al., 1998; Mezger et al., 1994; Murphy et al., 1994; Pirkkala et
al., 1999; Sarge et al., 1994; Sistonen et al., 1992). Our lab has previously shown that
HSF2 mRNA expression in subject to developmental, spermatogenic stage-specific, and
cell-type specific regulation in the testis (Sarge et al., 1994). The highest levels of HSF2
are found in pachytene spermatocytes and round spermatids. The DNA binding activity
of HSF2 is also regulated in the testis. In most cell types, HSF2 is found in a non-DNA
binding form. Testis expressed HSF2, alternatively, is found in a constitutively DNA
binding state (Sarge et al., 1994). Furthermore, the DNA binding form of HSF2 found in
the testis is capable of binding to promoter sequences from the hsp70.2 gene, a testis29
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specific hsp70 family member. This indicates that one function of HSF2 is to regulate
hsp gene expression during spermatogenesis (Sarge et al., 1994).
Previous results have suggested the existence of two distinct protein isoforms of
both HSF1 and HSF2 in mammalian cell (Sarge et al., 1993). In addition, sequence
comparison between the mouse and human homologues of HSF1 and HSF2 suggests that
these isoforms likely arise from alternative mRNA splicing (Figure 2.1). In order to
establish the mechanism by which these HSF protein isoforms arise, and to explore their
biological significance, we have characterized the expression of these HSF1 and HSF2
isoforms in cells of different mouse tissues.
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Figure 2.1: Human and mouse HSF DNA and protein sequence alignments.

(A) DNA sequence alignment between the human HSF1 (hHSF1) and mouse HSF1(β)
(mHSF1) homologues. The potential alternative mRNA processing region has been
bolded.

(B) Predicted protein sequence alignment between the human HSF1 (hHSF1) and mouse
HSF1(β) (mHSF1) homologues. The potential alternative mRNA processing region has
been bolded.

(C) DNA sequence alignment between the human HSF2 (hHSF2) and mouse HSF2(β)
(mHSF2) homologues. The potential alternative mRNA processing region has been
bolded.

(D) Predicted protein sequence alignment between the human HSF2 (hHSF2) and mouse
HSF2(β) (mHSF2) homologues. The potential alternative mRNA processing region has
been bolded.
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Figure 2.1 (A) Alignment of the DNA sequences of the human and mouse HSF1 open
reading frames.

hHSF1
mHSF1

ATGGATCTGC CCGTGGGCCC CGGCGCGGCG GGGCCCAGCA ACGTCCCGGC
ATGGATCTGG CCGTGGGCCC CGGTGCAGCG GGGCCCAGCA ACGTCCCGGC

hHSF1
mHSF1

CTTCCTGACC AAGCTGTGGA CCCTCGTGAG CGACCCGGAC ACCGACGCGC
CTTCCTAACC AAGCTGTGGA CCCTCGTGAG CGACCCGGAC ACAGACGCGC

hHSF1
mHSF1

TCATCTGCTG GAGCCCGAGC GGGAACAGCT TCCACGTGTT CGACCAGGGC
TCATCTGCTG GAGCCCGAGT GGGAACAGCT TCCACGTGTT TGACCAGGGC

hHSF1
mHSF1

CAGTTTGCCA AGGAGGTGCT GCCCAAGTAC TTCAAGCACA ACAACATGGC
CAGTTTGCCA AGGAGGTGCT GCCCAAGTAC TTCAAGCACA ACAACATGGC

hHSF1
mHSF1

CAGCTTCGTG CGGCAGCTCA ACATGTATGG CTTCCGGAAA GTGGTCCACA
TAGCTTCGTG CGGCAGCTCA ACATGTATGG CTTCCGAAAA GTAGTCCACA

hHSF1
mHSF1

TCGAGCAGGG CGGCCTGGTC AAGCCAGAGA GAGACGACAC GGAGTTCCAG
TTGAGCAGGG TGGCCTGGTC AAGCCTGAGA GAGATGACAC CGAGTTCCAG

hHSF1
mHSF1

CACCCATGCT TCCTGCGTGG CCAGGAGCAG CTCCTTGAGA ACATCAAGAG
CATCCTTGTT TCTTGCGTGG ACAGGAACAG CTCCTTGAGA ACATCAAGAG

hHSF1
mHSF1

GAAAGTGACC AGTGTGTCCA CCCTGAAGAG TGAAGACATA AAGATCCGCC
GAAAGTGACC AGCGTGTCCA CCCTGAAGAG TGAGGACATA AAAATACGCC

hHSF1
mHSF1

AGGACAGCGT CACCAAGCTG CTGACGGACG TGCAGCTGAT GAAGGGGAAG
AGGACAGTGT CACCCGGCTG TTGACAGATG TGCAGCTGAT GAAGGGGAAA

hHSF1
mHSF1

CAGGAGTGCA TGGACTCCAA GCTCCTGGCC ATGAAGCATG AGAATGAGGC
CAGGAGTGTA TGGACTCCAA GCTCCTGGCC ATGAAGCACG AGAACGAGGC

hHSF1
mHSF1

TCTGTGGCGG GAGGTGGCCA GCCTTCGGCA GAAGCATGCC CAGCAACAGA
CCTGTGGCGG GAGGTGGCCA GCCTTCGGCA GAAGCATGCC CAGCAGCAAA

hHSF1
mHSF1

AAGTCGTCAA CAAGCTCATT CAGTTCCTGA TCTCACTGGT GCAGTCAAAC
AAGTTGTCAA CAAGCTCATT CAGTTCCTGA TCTCACTGGT GCAGTCGAAC

hHSF1
mHSF1

CGGATCCTGG GGGTGAAGAG AAAGATCCCC CTGATGCTGA ACGACAGTGG
CGGATCCTGG GGGTGAAGAG AAAGATCCCT CTGATGTTGA GTGACAGCAA

hHSF1
mHSF1

CTCAGCACAT TCCATGCCCA AGTATAGCCG GCAGTTCTCC CTGGAGCACG
CTCAGCACAC TCTGTGCCCA AGTATGGTCG ACAGTACTCC CTGGAGCATG

hHSF1
mHSF1

TCCACGGCTC GGGCCCCTAC TCGGCCCCCT CCCCAGCCTA CAGCAGCTCC
TCCATGGTCC TGGCCCATAC TCAGCTCCAT CTCCAGCCTA CAGCAGCTCT

hHSF1
mHSF1

AGCCTCTACG CCCCTGATGC TGTGGCCAGC TCTGGACCCA TCATCTCCGA
AGCCTTTACT CCTCTGATGC TGTCACCAGC TCTGGACCCA TAATCTCCGA

hHSF1
mHSF1

CATCACCGAG CTGGCTCCTG CCAGCCCCAT GGCCTCCCCC GGCGGGAGCA
TATCACTGAG CTGGCTCCCA CCAGCCCTTT GGCCTCCCCA GGCAGGAGCA

hHSF1

TAGACGAGAG GCCCCTATCC AGCAGCCCCC TGGTGCGTGT CAAGGAGGAG
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mHSF1

TAGATGAGAG GCCTCTGTCC AGCAGCACTC TGGTCCGTGT CAAGCAAGAG

hHSF1
mHSF1

CCCCCCAGCC CGCCTCAGAG CCCCCGGGTA GAGGAGGCGA GTCCCGGGCG
CCCCCCAGCC CACCTCACAG CCCTCGGGTA CTGGAGGCGA GCCCTGGGCG

hHSF1
mHSF1

CCCATCTTCC GTGGACACCC TCTTGTCCCC GACCGCCCTC ATTGACTCCA
CCCATCCTCC ATGGATACCC CTTTGTCCCC AACTGCCTTC ATTGACTCCA

hHSF1
mHSF1

TCCTGCGGGA GAGTGAACCT GCCCCCGC-- -CTCCGTCAC AGCCCTCACG
TCCTTCGAGA GAGCGAGCCT ACCCCTGCTG CCTCAAACAC AGCCCCTATG

hHSF1
mHSF1

GACGCCAGGG GCCACACGGA CACCGAGGGC CGGCCTCCCT CCCCCCCGCC
GACAC----- ---AACCGGA GCCCAAG--- ----CCCCCG CACTCCCGAC

hHSF1
mHSF1

CACCTCCACC CCTGAAAAGT GCCTCAGCGT AGCCTGCCTG GACAAGAATG
CCCCTCCACC CCTGAGAAGT GCCTCAGCGT AGCCTGCCTA GACAAGAACG

hHSF1
mHSF1

AGCTCAGTGA CCACTTGGAT GCTATGGACT CCAACCTGGA TAACCTGCAG
AGCTAAGTGA TCACCTGGAT GCCATGGACT CCAACCTGGA CAACCTGCAG

hHSF1
mHSF1

ACCATGCTGA GCAGCCACGG CTTCAGCGTG GACACCAGTG CCCTGCTGGA
ACCATGCTGA CAAGCCACGG CTTCAGTGTG GACACCAGTG CCCTGCTGGA

hHSF1
mHSF1

CCTGTTCAGC CCCTCGGTGA CCGTGCCCGA CATGAGCCTG CCTGACCTTG
C--------- ---------- ---------- ---------- ----------

hHSF1
mHSF1

ACAGCAGCCT GGCCAGTATC CAAGAGCTCC TGTCTCCCCA GGAGCCCCCC
---------- -------ATT CAGGAGCTTC TGTCTCCACA AGAGCCTCCC

hHSF1
mHSF1

AGGCCTCCCG AGGCAGAGAA CAGCAGCCCG GATTCAGGGA AGCAGCTGGT
AGGCCTATTG AGGCAGAGAA CAGTAACCCC GACTCAGGAA AGCAGCTGGT

hHSF1
mHSF1

GCACTACACA GCGCAGCCGC TGTTCCTGCT GGACCCCGGC TCCGTGGACA
GCACTACACG GCTCAGCCTC TGTTCCTGCT GGATCCTGAT GCTGTGGACA

hHSF1
mHSF1

CCGGGAGCAA CGACCTGCCG GTGCTGTTTG AGCTGGGAGA GGGCTCCTAC
CAGGGAGCAG TGAGCTGCCT GTGCTCTTTG AGCTGGGGGA GAGCTCCTAC

hHSF1
mHSF1

TTCTCCGAAG GGGACGGCTT CGCCGAGGAC CCCACCATCT CCCTGCTGAC
TTCTCTGAGG GGGATGACTA CACGGATGAT CCCACCATCT CTCTTCTGAC

hHSF1
mHSF1

AGGCTCGGAG CCTCCCAAAG CCAAGGACCC CACTGTCTCC TAG
AGGCACTGAA CCCCATAAAG CCAAGGACCC CACTGTCTCC TAG
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Figure 2.1 (B) Alignment of the protein sequences of the human and mouse HSF1.

mHSF1
hHSF1

MDLAVGPGAA GPSNVPAFLT KLWTLVSDPD TDALICWSPS GNSFHVFDQG
MDLPVGPGAA GPSNVPAFLT KLWTLVSDPD TDALICWSPS GNSFHVFDQG

mHSF1
hHSF1

QFAKEVLPKY FKHNNMASFV RQLNMYGFRK VVHIEQGGLV KPERDDTEFQ
QFAKEVLPKY FKHNNMASFV RQLNMYGFRK VVHIEQGGLV KPERDDTEFQ

mHSF1
hHSF1

HPCFLRGQEQ LLENIKRKVT SVSTLKSEDI KIRQDSVTRL LTDVQLMKGK
HPCFLRGQEQ LLENIKRKVT SVSTLKSEDI KIRQDSVTKL LTDVQLMKGK

mHSF1
hHSF1

QECMDSKLLA MKHENEALWR EVASLRQKHA QQQKVVNKLI QFLISLVQSN
QECMDSKLLA MKHENEALWR EVASLRQKHA QQQKVVNKLI QFLISLVQSN

mHSF1
hHSF1

RILGVKRKIP LMLSDSNSAH SVPKYGRQYS LEHVHGPGPY SAPSPAYSSS
RILGVKRKIP LMLNDSGSAH SMPKYSRQFS LEHVHGSGPY SAPSPAYSSS

mHSF1
hHSF1

SLYSSDAVTS SGPIISDITE LAPTSPLASP GRSIDERPLS SSTLVRVKQE
SLYAPDAVAS SGPIISDITE LAPASPMASP GGSIDERPLS SSPLVRVKEE

mHSF1
hHSF1

PPSPPHSPRV LEASPGRPSS MDTPLSPTAF IDSILRESEP TPAASNTAPM
PPSPPQSPRV EEASPGRPSS VDTLLSPTAL IDSILRESEP APA-SVTALT

mHSF1
hHSF1

DTTG-----A QAPALPTPST PEKCLSVACL DKNELSDHLD AMDSNLDNLQ
DARGHTDTEG RPPSPPPTST PEKCLSVACL DKNELSDHLD AMDSNLDNLQ

mHSF1
hHSF1

TMLTSHGFSV DTSALLD--- ---------- ---------I QELLSPQEPP
TMLSSHGFSV DTSALLDLFS PSVTVPDMSL PDLDSSLASI QELLSPQEPP

mHSF1
hHSF1

RPIEAENSNP DSGKQLVHYT AQPLFLLDPD AVDTGSSELP VLFELGESSY
RPPEAENSSP DSGKQLVHYT AQPLFLLDPG SVDTGSNDLP VLFELGEGSY

mHSF1
hHSF1

FSEGDDYTDD PTISLLTGTE PHKAKDPTVS
FSEGDGFAED PTISLLTGSE PPKAKDPTVS
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Figure 2.1 (C) Alignment of the DNA sequences of the human and mouse HSF2 open
reading frames.

hHSF2
mHSF2

ATGAAGCAGA GTTCGAACGT GCCGGCTTTC CTCAGCAAGC TGTGGACGCT
ATGAAGCAGA GTTCCAACGT GCCGGCTTTC CTCAGCAAGC TGTGGACGCT

hHSF2
mHSF2

TGTGGAGGAA ACCCACACTA ACGAGTTCAT CACCTGGAGC CAGAATGGCC
TGTGGAGGAA ACCCACACCA ACGAGTTCAT CACCTGGAGT CAGAATGGAC

hHSF2
mHSF2

AAAGTTTTCT GGTCTTGGAT GAGCAACGAT TTGCAAAAGA AATTCTTCCC
AAAGTTTTCT GGTCTTGGAT GAGCAAAGAT TTGCAAAGGA AATTCTTCCT

hHSF2
mHSF2

AAATATTTCA AGCACAATAA TATGGCAAGC TTTGTGAGGC AACTGAATAT
AAGTACTTCA AACACAATAA CATGGCGAGC TTTGTGAGAC AACTAAATAT

hHSF2
mHSF2

GTATGGTTTC CGTAAAGTAG TACATATCGA CTCTGGAATT GTAAAGCAAG
GTATGGCTTC CGAAAAGTAG TGCATATCGA ATCTGGAATT ATCAAACAGG

hHSF2
mHSF2

AAAGAGATGG TCCTGTAGAA TTTCAGCATC CTTACTTCAA ACAAGGACAG
AAAGAGATGG CCCTGTTGAA TTTCAGCATC CTTATTTCAA GCAAGGCCAG

hHSF2
mHSF2

GATGACTTGT TGGAGAACAT TAAAAGGAAG GTTTCATCTT CAAAACCAGA
GATGACCTGT TGGAGAACAT TAAAAGGAAG GTTTCATCTT CAAAACCAGA

hHSF2
mHSF2

AGAAAATAAA ATTCGTCAGG AAGATTTAAC AAAAATTATA AGTAGTGCTC
GGAAAATAAA ATTCGTCAGG AAGATTTAAC AAAAATTATT AGTAGTGCTC

hHSF2
mHSF2

AGAAGGTTCA GATAAAACAG GAAACTATTG AGTCCAGGCT TTCTGAATTA
AGAAGGTTCA AATAAAACAA GAAACTATTG AGTCCAGGCT TTCAGAATTA

hHSF2
mHSF2

AAAAGTGAGA ATGAGTCCCT TTGGAAGGAG GTGTCAGAAT TACGAGCAAA
AAAAGTGAGA ATGAATCCCT TTGGAAGGAG GTGTCAGAAC TAAGAGCAAA

hHSF2
mHSF2

GCATGCACAA CAGCAACAAG TTATTCGAAA GATTGTCCAG TTTATTGTTA
GCATGCCCAG CAGCAACAAG TTATTCGGAA GATTGTCCAG TTTATTGTTA

hHSF2
mHSF2

CATTGGTTCA AAATAACCAA CTTGTGAGTT TAAAACGTAA AAGGCCTCTA
CATTGGTTCA GAATAATCAA CTTGTGAGTT TAAAACGTAA AAGGCCTCTA

hHSF2
mHSF2

CTTCTAAACA CTAATGGAGC CCAAAAGAAG AACCTGTTTC AGCACATAGT
CTTCTAAACA CAAATGGAGC CCCAAAGAAG AATCTATATC AGCACATAGT

hHSF2
mHSF2

CAAAGAACCA ACTGATAATC ATCATCATAA AGTTCCACAC AGTAGGACTG
CAAAGAACCA ACTGATAATC ACCATCATAA AGTTCCACAC AGCAGGACTG

hHSF2
mHSF2

AAGGTTTAAA GCCAAGGGAG AGGATTTCAG ATGACATCAT TATTTATGAT
AAGGTTTAAA GTCAAGAGAA CGGATTTCAG ATGACATAAT TATTTATGAT

hHSF2
mHSF2

GTTACTGATG ATAATGCAGA TGAAGAAAAT ATCCCAGTTA TTCCAGAAAC
GTTACTGACG ATAATGTGGA TGAAGAAAAT ATTCCAGTTA TTCCAGAAAC

hHSF2
mHSF2

TAATGAGGAT GTTATATCTG ATCCCTCCAA CTGTAGCCAG TACCCTGATA
AAATGAGGAT GTTGTAGTGG ATTCCTCCAA C------CAG TATCCTGACA

hHSF2

TTGTCATCGT TGAAGATGAC AATGAAGATG AGTATGCACC TGTCATTCAG
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mHSF2

TTGTCATTGT TGAAGATGAC AACGAGGATG AGTATGCTCC TGTCATTCAG

hHSF2
mHSF2

AGTGGAGAGC AGAATGAACC AGCCAGAGAA TCCCTAAGTT CAGGCAGTGA
AGTGGAGAGC AGAGTGAACC AGCCAGAGAA CCCTTACGTG TGGGGAGTGC

hHSF2
mHSF2

TGGCAGCAGC ---CCTCTCA TGTCTAGTGC TGTCCAGCTA AATGGCTCAT
TGGCAGCAGC AGCCCTCTCA TGTCTAGTGC TGTCCAGCTA AACGGCTCCT

hHSF2
mHSF2

CCAGTCTGAC CTCAGAAGAT CCAGTGACCA TGATGGATTC CATTTTGAAT
CCAGTCTGAC CTCAGAAGAC CCTGTGACCA TGATGGACTC CATTCTGAAT

hHSF2
mHSF2

GATAACATCA ATCTTTTGGG AAAGGTTGAG CTGTTGGATT ATCTTGACAG
GACAACATTA ACCTGTTAGG AAAGGTTGAG CTGTTGGATT ACCTTGACAG

hHSF2
mHSF2

TATTGACTGC AGTTTAGAGG ACTTCCAGGC CATGCTATCA GGAAGACAAT
TATTGATTGC AGTTTAGAGG ACTTCCAAGC TATGCTCTCA GGAAGACAGT

hHSF2
mHSF2

TTAGCATAGA CCCAGATCTC CTGGTTGATC TTTTCACTAG TTCTGTGCAG
TTAGCATAGA CCCAGATCTT CTGGTTGAT- ---------- ----------

hHSF2
mHSF2

ATGAATCCCA CAGATTACAT CAATAATACA AAATCTGAGA ATAAAGGATT
---------- ---------- ---------- ---TCTGAGA ATAAGGGACT

hHSF2
mHSF2

AGAAACTACC AAGAACAATG TAGTTCAGCC AGTTTCGGAA GAGGGAAGAA
AGAAGCTACC AAGAGCAGTG TTGTTCAACA TGTGTCAGAA GAGGGAAGAA

hHSF2
mHSF2

AATCTAAATC CAAACCAGAT AAGCAGCTTA TCCAGTATAC CGCCTTTCCA
AATCTAAATC CAAGCCAGAC AAACAACTTA TCCAGTATAC TGCCTTTCCA

hHSF2
mHSF2

CTTCTTGCAT TCCTCGATGG GAACCCTGCT TCTTCTGTTG AACAGGCGAG
CTTCTTGCAT TCCTGGATGG GAACTCTGCA TCTGCTATTG AACAGGGGAG

hHSF2
mHSF2

TACAACAGCA TCATCAGAAG TTTTGTCCTC TGTAGATAAA CCCATAGAAG
TACAACTGCA TCGTCAGAAG TTGTGCCTTC TGTAGATAAA CCCATAGAAG

hHSF2
mHSF2

TTGATGAGCT TCTGGATAGC AGCCTAGACC CAGAACCAAC CCAAAGTAAG
TCGATGAGCT CCTGGATAGC AGCCTGGATC CAGAACCGAC CCAGAGTAAG

hHSF2
mHSF2

CTTGTTCGCC TGGAGCCATT GACTGAAGCT GAAGCTAGTG AAGCTACACT
CTTGTCCGCC TGGAACCATT GACTGAAGCG GAAGCTAGTG AAGCCACACT

hHSF2
mHSF2

GTTTTATTTA TGTGAACTTG CTCCTGCACC TCTGGATAGT GATATGCCAC
CTTCTATTTA TGTGAACTTG CTCCTGCACC TCTGGATAGT GATATGCCGC

hHSF2
mHSF2

TTTTAGATAG CTAA
TTTTAGATAG TTAA
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Figure 2.1 (D) Alignment of the protein sequences of the human and mouse HSF1.
mHSF2
hHSF2

MKQSSNVPAF LSKLWTLVEE THTNEFITWS QNGQSFLVLD EQRFAKEILP
MKQSSNVPAF LSKLWTLVEE THTNEFITWS QNGQSFLVLD EQRFAKEILP

mHSF2
hHSF2

KYFKHNNMAS FVRQLNMYGF RKVVHIESGI IKQERDGPVE FQHPYFKQGQ
KYFKHNNMAS FVRQLNMYGF RKVVHIDSGI VKQERDGPVE FQHPYFKQGQ

mHSF2
hHSF2

DDLLENIKRK VSSSKPEENK IRQEDLTKII SSAQKVQIKQ ETIESRLSEL
DDLLENIKRK VSSSKPEENK IRQEDLTKII SSAQKVQIKQ ETIESRLSEL

mHSF2
hHSF2

KSENESLWKE VSELRAKHAQ QQQVIRKIVQ FIVTLVQNNQ LVSLKRKRPL
KSENESLWKE VSELRAKHAQ QQQVIRKIVQ FIVTLVQNNQ LVSLKRKRPL

mHSF2
hHSF2

LLNTNGAPKK NLYQHIVKEP TDNHHHKVPH SRTEGLKSRE RISDDIIIYD
LLNTNGAQKK NLFQHIVKEP TDNHHHKVPH SRTEGLKPRE RISDDIIIYD

mHSF2
hHSF2

VTDDNVDEEN IPVIPETNED VVVDSSN--Q YPDIVIVEDD NEDEYAPVIQ
VTDDNADEEN IPVIPETNED VISDPSNCSQ YPDIVIVEDD NEDEYAPVIQ

mHSF2
hHSF2

SGEQSEPARE PLRVGSAGSS SPLMSSAVQL NGSSSLTSED PVTMMDSILN
SGEQNEPARE SLSSGSDGSS -PLMSSAVQL NGSSSLTSED PVTMMDSILN

mHSF2
hHSF2

DNINLLGKVE LLDYLDSIDC SLEDFQAMLS GRQFSIDPDL LVD------DNINLLGKVE LLDYLDSIDC SLEDFQAMLS GRQFSIDPDL LVDLFTSSVQ

mHSF2
hHSF2

---------- -SENKGLEAT KSSVVQHVSE EGRKSKSKPD KQLIQYTAFP
MNPTDYINNT KSENKGLETT KNNVVQPVSE EGRKSKSKPD KQLIQYTAFP

mHSF2
hHSF2

LLAFLDGNSA SAIEQGSTTA SSEVVPSVDK PIEVDELLDS SLDPEPTQSK
LLAFLDGNPA SSVEQASTTA SSEVLSSVDK PIEVDELLDS SLDPEPTQSK

mHSF2
hHSF2

LVRLEPLTEA EASEATLFYL CELAPAPLDS DMPLLDS
LVRLEPLTEA EASEATLFYL CELAPAPLDS DMPLLDS
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We found that mouse cells express two distinct HSF1 mRNA isoforms (HSF1- α
and HSF1- β) that are generated by alternative splicing of the HSF1 pre-mRNA. The two
HSF1 mRNA isoforms result from the inclusion (HSF1- α), or omission (HSF1- β), of a 66
nucleotide exon of the HSF1 gene, which encodes a 22 amino acid sequence. The
insertion site of this 22 amino acid sequence in the HSF1- α isoform is located
immediately adjacent to a C-terminal leucine zipper motif shown by other studies to be
involved in maintenance of HSF1 in the non-DNA-binding control form (Rabindran et
al., 1993; Zuo et al., 1994). Our results also show that the levels of the HSF1- α and
HSF1- β mRNA isoforms are regulated in a tissue-dependent manner, with testis
expressing predominantly the HSF1- β isoform while heart and brain express primarily the
HSF1- α isoform.
In addition, we found that mouse cells also express two distinct HSF2 mRNA
isoforms (HSF2- α and HSF2- β) that are generated by alternative splicing of the HSF2
pre-mRNA. The two HSF2 mRNA isoforms result from the inclusion (HSF2- α), or
omission (HSF2- β), of a 54 nucleotide exon of the HSF2 gene, which encodes a 18 amino
acid sequence. Like HSF1, the insertion site of this 18 amino acid sequence in the HSF2α isoform is located immediately adjacent to a C-terminal leucine zipper motif

(Rabindran et al., 1993; Zuo et al., 1994). Our results also show that the levels of the
HSF2- α and HSF2- β mRNA isoforms are regulated in a tissue-dependent manner, with
testis and brain expressing predominantly the HSF2- α isoform while heart, liver, and
kidney express primarily the HSF2- β isoform. Furthermore, HSF2 isoform levels are
regulated both in a developmental and cell type dependent manner in the testis. Newborn
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mice express predominantly the HSF2- β isoform in the testis through day 14. Beginning
around day 21 and in the adult mouse, the HSF2- α isoform is the predominant HSF2
isoform expressed in the testis. During spermatogenesis, pachytene spermatocytes and
round spermatids express predominantly the HSF2- α isoform. We have also
characterized both HSF2 isoforms with respect to transcriptional activity. In a luciferase
reporter gene assay, HSF2- α is a 2.6-fold better transcriptional activator than the HSF2- β
isoform. These data suggest that the HSF2 isoforms may have functionally distinct
biological roles.

MATERIALS AND METHODS

Experimental Animals

CBA/J mice were obtained from Jackson Laboratory (Bar Harbor, ME) and
maintained under a controlled light cycle (14 hrs. light:10 hrs. dark). Heart, brain, and
testes were removed from mice at the age of 6-8 weeks, rapidly frozen on dry ice, and
then stored at -80°C until use. These studies were conducted in accordance with the
procedures described in the NIH Guide for the Care and Use of Laboratory Animals.

RT-PCR Analysis

Total RNA was prepared from adult mouse tissues by homogenization in
guanidine isothiocyanate and centrifugation through cesium chloride, as described
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previously (Sarge et al., 1994). For RT-PCR, reverse transcription coupled with
polymerase chain reaction, total RNA (2-5 µg) was reverse-transcribed at 42°C using
random hexamer primers and AMV reverse transcriptase (6 U) in a 20 µl reaction. Two
oligonucleotide primers, which hybridize to nucleotides 1272-1293 (5’-GCTAA GTGAT
CACCT GGATG CC-3’) and 1730-1751 (5’-TCCCC TGGAC TACCC ACCTG TT-3’)
of the mouse HSF1 cDNA, were used to amplify 479 bp and 545 bp isoform products
from the HSF1 cDNA. Two oligonucleotide primers, which hybridize to nucleotides
1171-1192 (5’- ACCCT GTGAC CATGA TGGAC TC-3’) and 1623-1644 (5’-TGGCT
TCACT AGCTT CCGCT TC-3’) of the mouse HSF2 cDNA, were used to amplify 473
bp and 527 bp isoform products from the HSF2 cDNA. For both HSF1 and HSF2, an
internal control 104 bp fragment was amplified from the mouse ribosomal protein S16
mRNA (5’-TCCAA GGGTC CGCTG CAGTC-3’ and 5’-CGTTC ACCTT GATGA
GCCCA TT-3’) (14). A reaction cocktail containing oligonucleotide primers (200 ng
each), [α- 32P]-dCTP (2 µCi at 3000 Ci/mmole), 10 X PCR buffer (10 mM Tris, pH 8.3,
50 mM KCl, 1.5 mM MgCl2, 0.01% gelatin--Perkin Elmer) and AmpliTaq DNA
polymerase (2.5 U, Perkin Elmer) was added to each reaction. The total volume was
brought to 100 µl with distilled water, and the sample overlaid with mineral oil.
Amplification was carried out for 20 cycles using an annealing temperature of 65°C in a
Perkin-Elmer Cetus thermal cycler. The amplified products were separated by
electrophoresis on 5% polyacrylamide gels and visualized by film autoradiography.
Intensity of bands in the RT-PCR analysis were quantified with a Molecular Dynamics
Phosphorimager using the ImageQuant program (version 3.3), and the levels of the
isoform bands were calculated after normalization to the S16 mRNA internal control.
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Isolation and Cloning of HSF1 cDNA and Genomic DNA Sequences

The fragments of the HSF1 and HSF2 cDNAs spanning the alternative splice sites
were obtained by RT-PCR methods from total RNA of mouse testis. Following reverse
transcription of total RNA, cDNA fragments were amplified by PCR as described above
with the exception that radioactivity was not incorporated and 30 cycles of PCR were
used to amplify the DNA. HSF1 cDNA fragments were digested using the restriction
endonucleases NcoI (1296 nt) and SacI (1549 nt) on opposite sides of the splice variant
junctions and were subcloned into the pGEM-5Z (Promega, Madison, WI) plasmid
vector. HSF2 cDNA fragments were subcloned into the plasmid vector pSP72 (Promega,
Madison, WI) using the restriction endonucleases BglII (1315 nt) and HindIII (1595 nt)
which are located on opposite sides of the splice variant region of the HSF2 cDNA. The
sequences were determined by the Sanger dideoxy method according to the protocol from
the Sequenase DNA sequencing kit (USB, Cleveland, OH).
The genomic DNA sequences of the HSF1 and HSF2 genes that comprise the
alternative splice junctions were isolated from HSF1 and HSF2 genomic DNA phage
clones obtained from a mouse genomic DNA library. The fragments containing the
alternative splice junctions of HSF1 and HSF2 were subcloned into pGEM-5Z and pSP72
plasmids respectively using the restriction endonuclease sites indicated above. The
sequences were determined by the Sanger dideoxy method according to the protocol from
the Sequenase DNA sequencing kit (USB, Cleveland, OH).
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Western Blot (Immunoblot) and Gel Mobility Shift Analysis

Mouse tissues and isolated spermatogenic cells (pachytene spermatocytes and
round spermatids) were resuspended and boiled for 5 min in 2x Laemmli SDS-PAGE
buffer [125 mM TrisHCl, pH 6.8, 20% glycerol, 4% sodium dodecylsulfate (SDS) and
200 mM dithiothreitol (DTT)] (Laemmli, 1970). Samples were electrophoresed on an
8% SDS-polyacrylamide gel (Laemmli, 1970) and transferred to nitrocellulose using a
BIORAD Semidry transfer apparatus (BIORAD, Hercules, CA) according to the
manufacturer’s protocol. The blot was probed with the HSF2 polyclonal antiserum as
previously described (Sarge et al., 1993). The native gel mobility 47shift assay was
performed as described previoulsly (Sarge et al., 1993) with a self-complementary
consensus heat shock-element-containing oligonucleotide (5’CTAGAAGCTTCTAGAAGCTTCTAG-3’), which contains four perfect inverted 5’NGAAN-3’ repeats.

HSF2 Transfection of NIH 3T3 Cells and Luciferase Assays

NIH 3T3 Cells were transfected with plasmid vectors which contained either the
HSF2- α or HSF2- β cDNA under the control of the β-actin promoter and a reporter
plasmid with the firefly luciferase gene under the control of the hsp promoter (Sarge et
al., 1993). The β-actin-HSF2- α vector was made by subcloning the splice variant region
of the HSF2- α cDNA from the pSP-HSF2- α vector described above into the β-actinHSF2- β vector described previously using BglII and HindIII. NIH 3T3 cells were
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transfected using calcium phosphate described previously (Espeseth et al., 1989). In
short, cells were seeded at 5x105 cells per 10 cm tissue culture plate in DMEM containing
10% fetal bovine serum and 50µg/ml gentamycin. The following day cells were
transfected with 10 µg of DNA and incubated at 37º C overnight. Fresh medium was
added the next morning. After 24h cells were harvested and whole cell extracts were
made as previously described (Sarge et al., 1993). Luciferase assays were performed as
previously described and the results were normalized to transfection efficiency as
previously described (de Wet et al., 1987). Western blot and gel mobility shift assays
were performed as described above.

RESULTS

Tissue distribution of HSF1 mRNA isoforms.

Previous western blot analysis of the HSF1 protein in NIH-3T3 cell extracts
treated with potato acid phosphatase revealed the existence of two major HSF1 protein
isoforms of approximately 69 and 71 kDa molecular weight (Sarge et al., 1993). We will
refer to the 71 kDa protein as the HSF1- α isoform and the 69 kDa protein as the HSF1- β
isoform. Phosphatase treatment was necessary to reveal these HSF1 protein isoforms
because the HSF1 protein in unstressed cells exhibits multiple phosphorylation states,
which results in a heterogeneous migration of the HSF1 protein on SDS-PAGE gel
(Sarge et al., 1993). In order to determine whether the HSF1- α and HSF1- β protein
isoforms arise via alternative splicing of the HSF1 pre-mRNA, we performed RT-PCR
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analysis of HSF1 mRNA in various mouse tissues. For this analysis, we used primer
pairs that amplify a region in the HSF1 mRNA that was suggested by previous sequence
analysis to be subject to alternative splicing events. This sequence comparison of
previously cloned human and mouse cDNAs revealed a 22 amino acid gap in homology
between the mouse and human HSF1 (Figure 2.1, (Rabindran et al., 1991; Sarge et al.,
1991)). The results of the RT-PCR analysis, shown in Figure 2.2 A, demonstrate the
existence of two distinct HSF1 mRNA variants (HSF1- α and HSF1- β) in these tissues.
This analysis also revealed that the levels of these two HSF1 mRNA isoforms are
regulated in a tissue-dependent manner. Quantification of the results of the RT-PCR
analysis revealed that heart and brain express 2.0 and 1.6-fold higher levels of the HSF1α mRNA isoform, respectively, while testis expresses 2.2-fold higher levels of the HSF1β mRNA isoform (Figure 2.2B).

Tissue distribution of HSF2 mRNA isoforms.

Similarly, western blot analysis of the HSF2 protein in mouse tissue extracts from
heart, brain, testes, and isolated spermatogenic cell types (pachytene spermatocytes and
round spermatids) revealed the existence of two major HSF2 protein isoforms of
approximately 69 and 71 kDa molecular weight (Figure 2.3). Again, we will refer to the
71 kDa protein as the HSF2- α isoform and the 69 kDa protein as the HSF2- β isoform. In
is unnecessary to treat extracts with potato acid phosphatase prior to analysis for HSF2
protein, as HSF2 does not contain the same phosphorylation-induced heterogeneous
SDS-PAGE migration as does HSF1 (Sarge et al., 1993). In order to determine whether
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the HSF2- α and HSF2- β protein isoforms arise via alternative splicing of the HSF2 premRNA, we performed RT-PCR analysis of HSF2 mRNA in various mouse tissues. For
this analysis, we used primer pairs that amplify a region in the HSF2 mRNA that was
suggested by previous sequence analysis to be subject to alternative splicing events. This
sequence comparison of previously cloned human and mouse cDNAs revealed a 18
amino acid gap in homology between the mouse and human HSF2 (Figure 2.1, (Sarge et
al., 1991; Schuetz et al., 1991)). The results of the RT-PCR analysis, shown in Figure
2.4A, demonstrate the existence of two distinct HSF2 mRNA variants (HSF2- α and
HSF2- β) in these tissues. This analysis also revealed that the levels of these two HSF2
mRNA isoforms are regulated in a tissue-dependent manner. Quantification of the results
of the RT-PCR analysis revealed that heart and brain express 2.8 and 5.3-fold higher
levels of the HSF2- β mRNA isoform, respectively, while testis overall expresses 1.9-fold
higher levels of the HSF1- α mRNA isoform. Pachytene spermatocytes and round
spermatids each express 2.6 and 2.1-fold higher levels of the HSF2- β mRNA isoform,
respectively (Figure 2.4B).

Cloning of HSF1 cDNA isoforms.

In order to verify the identity of the HSF1 mRNA variants, the PCR products
amplified from testis total RNA (as seen in Figure 2.2A) were cloned and sequenced.
The sequence analysis, shown in Figure 2.5, reveals that the HSF1- β mRNA isoform
corresponds to a previously cloned HSF1 cDNA (Sarge et al., 1991). The larger HSF1- α
mRNA isoform differs from the HSF1- β isoform by the insertion of an additional 66
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nucleotides, which encode a 22 amino acid sequence. The theoretical molecular weight
of the additional 22 amino acids is 2.3 kDa, which is consistent with the difference in size
between the HSF1- α and HSF1- β protein isoforms (71 and 69 kDa, respectively) (Sarge
et al., 1993).

Cloning of HSF2 cDNA isoforms.

In order to verify the identity of the HSF2 mRNA variants, the PCR products
amplified from testis total RNA (as seen in Figure 5A) were cloned and sequenced. The
sequence analysis, shown in Figure 2.6, reveals that the HSF2- β mRNA isoform
corresponds to a previously cloned HSF2 cDNA (Sarge et al., 1991). The larger HSF2- α
mRNA isoform differs from the HSF2- β isoform by the insertion of an additional 54
nucleotides, which encode a 18 amino acid sequence. The theoretical molecular weight
of the additional 18 amino acids is 2.0 kDa, which is consistent with the difference in size
between the HSF2- α and HSF2- β protein isoforms (71 and 69 kDa, respectively) (Sarge
et al., 1993).

Cloning of the HSF1 genomic DNA from the splice variant region.

In order to obtain definitive evidence that the HSF1- α and HSF1- β mRNA
isoforms arise via an alternative splicing mechanism, the regions of the HSF1 gene
corresponding to the putative alternative splice junctions were isolated from a genomic
library and sequenced. This sequence analysis, shown in Figure 2.7, reveals the existence
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of a 66 bp exon in the HSF1 gene that corresponds to the extra nucleotide sequence in the
HSF1- α mRNA isoform. This exon is bounded by intronic sequences of 76 and 68 bp,
both of which exhibit mammalian splice site consensus sequences. These results show
that the HSF1- α and HSF1- β mRNA isoforms are generated by alternative splicing of the
HSF1 pre-mRNA.
Shown in Figure 2.8 is a schematic representation of the alternative splicing
events by which the HSF1- α and HSF1- β isoforms are generated. The additional 22
amino acid sequence (denoted SV) is inserted in the C-terminal region of the HSF1
protein, immediately adjacent to a previously identified leucine zipper motif (Leucine
Zipper 4).

HSF1- α splicing creates a fifth potential leucine zipper.

Figure 2.9 shows that the addition of the extra 22 amino acid sequence in the
HSF1- α protein results in the appearance of a new, previously unidentified leucine zipper
motif in this HSF1 isoform, which we will refer to as Leucine Zipper 5 (LZ-5).
Comparison of the mouse HSF1- α sequence with the orthologous human and Drosophila
HSF sequences shows that the heptad repeats of hydrophobic amino acids that comprise
Leucine Zipper 5 (indicated by open and closed diamonds) have been evolutionarily
conserved (17,15), suggesting that this leucine zipper motif may be important for HSF
function. This figure also shows the proximity of this new Leucine Zipper 5 motif to the
hydrophobic amino acid heptad repeats of the previously identified Leucine Zipper 4
(indicated by open and closed triangles). Leucine Zipper 4 has been shown to be
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important for maintenance of HSF1 in the non-DNA binding state, presumably via its
interaction with leucine zipper sequences in the N-terminal oligomerization domain
(Rabindran et al., 1993; Zuo et al., 1994). The close spatial relationship of these two
leucine zipper motifs suggests that Leucine Zipper 5 may also be involved in interactions
important for the HSF1 non-DNA-binding state. The HSF1- β protein isoform, since it
lacks the additional 22 amino acid sequence, does not contain the Leucine Zipper 5 motif.

Cloning of the HSF2 genomic DNA from the splice variant region.

In order to obtain definitive evidence that the HSF2- α and HSF2- β mRNA
isoforms arise via an alternative splicing mechanism, the region of the HSF2 gene
corresponding to the putative alternative splice junctions was isolated from a genomic
library and partially sequenced. This sequence analysis, shown in Figure 2.10, reveals
the existence of a 54 bp exon in the HSF2 gene that corresponds to the extra nucleotide
sequence in the HSF2- α mRNA isoform. This exon is bounded by intronic sequences of
approximately 1.8 kb and 2.3 kb, both of which exhibit mammalian splice site consensus
sequences. These results show that the HSF2- α and HSF2- β mRNA isoforms are
generated by alternative splicing of the HSF2 pre-mRNA.
Shown in Figure 2.11 is a schematic representation of the alternative splicing
events by which the HSF1- α and HSF1- β isoforms are generated. The additional 18
amino acid sequence (denoted SV) is inserted in the C-terminal region of the HSF2
protein, immediately adjacent to a previously identified leucine zipper motif (Leucine
Zipper 4).

49

Developmental Regulation of HSF2 mRNA Splicing.

HSF2 mRNA and protein levels are highly regulated during development and
spermatogenesis (Sarge et al., 1994). Also, pachytene spermatocytes and round
spermatids express high levels of HSF2- α, more than whole testes (Figure 2.4). Based on
these facts, we sought to determine if the expression of the HSF2 isoforms was regulated
during development. To this end, we performed RT-PCR on mRNA from testes
harvested from mice at various stages of postnatal development. At seven days
postpartum, testes contain only somatic cells. At this stage HSF2- β is the predominant
isoform of HSF2 expressed in the testis. From days 14 and 21 through adulthood (six
weeks), levels of the HSF2- α isoform increase (Figure 2.12a). Quantification of the RTPCR analysis after normalization to the S-16 internal standard reveals that the change
from HSF2- β to HSF2- α over the course of postnatal development is primarily due to
increased levels of HSF2- α expression (Figure 2.12b). This result is consistent with the
increase in germ cells relative to somatic cells with the onset of spermatogenesis.

Increased transcriptional activity of the HSF2- α isoform.

Finally, we sought to determine if there were functional differences between the HSF2
isoforms. To assess differences in transcriptional activity, the two isoforms were
analyzed using a reporter gene assay. NIH 3T3 cells were cotransfected with an HSF2- α
or HSF2- β expression plasmid and a reporter plasmid with the firefly luciferase gene
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under the control of the mammalian hsp70 promoter. Transcriptional activity was
measured as changes in luciferase activity relative to cells transfected with parental βactin-1-neo parental vector the reporter plasmid. Luciferase activity was determined by
measuring the amount of light given off from cell extracts when luciferin and ATP were
added. These results were normalized to total protein in the cell extracts.
From this analysis, we determined that HSF2- β and HSF2- α were capable of
activating transcription of the reporter gene 3.6-fold and 9.6-fold respectively (Figure
2.13a). Analysis of the HSF2 protein levels of the transfected cell extracts used for the
luciferase assays by western blotting indicates that differences in the transcriptional
activity were not to due to differences in transfection efficiency, expression levels, or
overall protein stability. Both HSF2- α and HSF2- β transfected cells had relatively
similar protein levels (Figure 2.13b). Also, levels of HSF2- α and HSF2- β were each
significantly increased in the respective cotransfected cell extracts over the cells
transfected with the reporter plasmid alone. Furthermore, gel mobility shift analysis
revealed that both the HSF2- α and HSF2- β transfected cells had similar levels of HSE
DNA binding activity (Figure 2.13c). Thus inclusion of the 18 amino acid peptide
confers a 2.6 fold greater transcriptional potency on the HSF2- α isoform over HSF2- β.
These data suggest that HSF2- α may be playing a functionally distinct role from HSF2- β,
by providing increased levels of transcription of hsp genes in cells expressing
predominantly the HSF2- α isoform. This may particularly relevant to the process of
spermatogenesis, as pachytene spermatocytes and round spermatids express
predominantly the HSF2- α isoform in the DNA binding form.
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Figure 2.2: RT-PCR analysis of HSF1 mRNA isoforms in mouse tissues.

(A) Total RNA from mouse heart (H), brain (B), testis (T), was subjected to RT-PCR
analysis using an oligonucleotide primer pair that amplifies the region corresponding to
nucleotides 1272 to 1751 of the full-length mouse HSF1 cDNA (16). (B) Quantification
of HSF1- α and HSF1- β mRNA isoform levels in mouse tissues. The HSF1- α and HSF1β

RT-PCR bands in panel A were quantified and normalized to values of S16 mRNA

internal control bands.
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Figure 2.2: RT-PCR analysis of HSF1 mRNA isoforms in mouse tissues.
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Figure 2.3 : Western blot analysis of HSF2 protein from mouse tissues.

Western blot analysis of HSF2 protein in mouse tissue extracts from heart (H), brain (B),
testes, and the isolated spermatogenic cell types pachytene spermatocytes (PS) and round
spermatids (RS) reveals the existence of two major HSF2 protein isoforms of
approximately 69 and 71 kDa molecular weight.
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Figure 2.3: Western blot analysis of HSF2 protein from mouse tissues.
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Figure 2.4: RT-PCR analysis of HSF2 mRNA isoforms in mouse tissues.

(A) Total RNA from mouse heart (H), brain (B), testis (T), pachytene spermatocytes
(PS), and round spermatids (RS) was subjected to RT-PCR analysis using an
oligonucleotide primer pair that amplifies the region corresponding to nucleotides 1171
to 1643 of the full-length mouse HSF2 cDNA (16). (B) Quantification of HSF2- α and
HSF2- β mRNA isoform levels in mouse tissues. The HSF1- α and HSF1- β RT-PCR
bands in panel A were quantified and normalized to values of S16 mRNA internal control
bands.
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Figure 2.4: RT-PCR analysis of HSF2 mRNA isoforms in mouse tissues.
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Figure 2.5: Nucleotide and deduced amino acid sequences of HSF1 mRNA isoform
cDNAs.

RT-PCR products corresponding to HSF1- α and HSF1- β mRNA isoforms (as shown in
Figure 3A) were isolated, subcloned, and sequenced. The nucleotide and deduced amino
acid sequences shown correspond to the region of variation between the HSF1- α and
HSF1- β mRNA isoforms. Numbers refer to nucleotide position relative to the previously
cloned full-length mouse HSF1 cDNA (Sarge et al., 1991).
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Figure 2.5: Nucleotide and d educed amino acid sequences of HSF1 mRNA isoform
cDNAs.

ser ala leu leu asp leu phe ser pro ser val thr met pro asp met ser leu
-//- AGT GCC CTG CTG GAC CTA TTC AGC CCC TCG GTG ACC ATG CCC GAC ATG AGC CTG
-//- AGT GCC CTG CTG GAC - - - - - - - - - - - - - - - - - - - - - - - - - |
1361

pro asp leu asp cys ser leu ala ser ile gln glu leu leu
CCT GAC CTG GAC TGC AGC CTG GCC AGC ATT CAG GAG CTT CTG-//- mHSF1-α
- - - - - - - - - - - - - - - - - - ATT CAG GAG CTT CTG-//- mHSF1-β
|
1390
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Figure 2.6: Nucleotide and deduced amino acid sequences of HSF2 mRNA isoform
cDNAs.

RT-PCR products corresponding to HSF2- α and HSF2- β mRNA isoforms (as shown in
Figure 5A) were isolated, subcloned, and sequenced. The nucleotide and deduced amino
acid sequences shown correspond to the region of variation between the HSF2- α and
HSF2- β mRNA isoforms. Numbers refer to nucleotide position relative to the previously
cloned full-length mouse HSF2 cDNA (Sarge et al., 1991).

60
Figure 2.6: Nucleotide and deduced amino acid sequences of HSF2 mRNA isoform
cDNAs.

asp leu leu val asp leu phe thr ser ser val gln met asn pro thr
[--//-- GAT CTT CTG GTT GAT CTT TTC ACT AGT TCT GTG CAG ATG AAT CCC ACA
[--//-- GAT CTT CTG GTT GAT - - - - - - - - - - - - - - - - - - - - - |
1317

asp asn ile asn asn thr lys ser glu asn lys gly
GAT AAC ATC AAT AAT ACA AAA TCT GAG AAT AAG GGA --//--] mHSF2-α cDNA
- - - - - - - - - - - - - - TCT GAG AAT AAG GGA --//--] mHSF2-β cDNA
|
1347
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Figure 2.7: Sequence of HSF1 gene regions corresponding to alternative splice
junctions.

An HSF1 genomic fragment containing the exon-intron boundaries of interest was
isolated from a mouse genomic library, subcloned, and sequenced. Exons are shown as
bold capital type while introns are shown as normal lower-case type. Numbers at the
beginning and end of the genomic sequences are nucleotide positions relative to the fulllength mouse HSF1 cDNA (Sarge et al., 1991), which are the same as those indicated in
Figure 6 in order to allow easy comparison of the corresponding HSF1 mRNA isoform
and gene sequences.
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Figure 2.7: Sequence of HSF1 gene regions corresponding to alternative splice
junctions.

1361

AGTGCCCTGC TGGACgtgag tctggtcatc cctacccacc ctgctccatc ctgcccacaa
TCACGGGACG ACCTGcactc agaccagtag ggatgggtgg gacgaggtag gacgggtgtt
gccagccctg actccctccc tcctcctgca gCTATTCAGC CCCTCGGTGA CCATGCCCGA
cggtcgggac tgagggaggg aggaggacgt cGATAAGTCG GGGAGCCACT GGTACGGGCT
CATGAGCCTG CCTGACCTGG ACTGCAGCCT GGCCAGCgtg cgtaggcggg cagggtgggg
GTACTCGGAC GGACTGGACC TGACGTCGGA CCGGTCGcac gcatccgccc gtcccacccc
ggggcagagg ggggccatca acaacctatg tgttcctgtc cacagATTCA GGAGCTTCGT 1390
ccccgtctcc ccccggtagt tgttggatac acaaggacag gtgtcTAAGT CCTCGAAGAC
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Figure 2.8: Schematic representation of HSF1 mRNA alternative splicing.

Schematic representation of HSF1 mRNA alternative splicing pathways and functional
domains of HSF1- α and HSF1- β protein isoforms. The HSF1 exon encoding the 22
amino acid sequence which differs in the HSF1 isoforms is indicated (SV), along with the
conserved DNA-binding domain, oligomerization domain (LZ's 1, 2, 3), and carboxyterminal leucine zipper motif (LZ-4).
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Figure 2.8: Schematic representation of HSF1 mRNA alternative splicing.
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Figure 2.9: Novel leucine zipper motif in HSF1- α .

Regions of the amino acid sequences of the mouse HSF1- α, human HSF1 and Drosophila
HSF homologs corresponding to leucine zipper 4 (LZ-4) and the alternative splice
junction of the mouse HSF1 protein were aligned. The sequences were then analyzed to
identify potential heptad hydrophobic amino acid repeats characteristic of leucine zipper
motifs. Open (∆) and closed (s) triangles correspond to the two registers of the
previously identified LZ-4 (15). Open ( ) and closed (u) diamonds indicate the
hydrophobic amino acids which comprise the newly identified leucine zipper 5 (LZ-5).
Numbers at the beginning and end of the sequences refer to positions relative to the
published full-length amino acid sequences.
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Figure 2.9: Novel leucine zipper motif in HSF1- α .
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Figure 2.10: Sequence of HSF2 gene regions corresponding to alternative splice
junctions.

An HSF2 genomic fragment containing the exon-intron boundaries of interest was
isolated from a mouse genomic library, subcloned, and partially sequenced. Exons are
shown as bold capital type while introns are shown as normal lower-case type. Numbers
at the beginning and end of the genomic sequences are nucleotide positions relative to the
full-length mouse HSF2 cDNA (Sarge et al., 1991), which are the same as those indicated
in Figure 7 in order to allow easy comparison of the corresponding HSF1 mRNA isoform
and gene sequences.
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Figure 2.10: Sequence of HSF2 gene regions corresponding to alternative splice
junctions.
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Figure 2.11: Schematic representation of HSF2 mRNA alternative splicing.

Schematic representation of HSF2 mRNA alternative splicing pathways and functional
domains of HSF2- α and HSF2- β protein isoforms. The HSF2 exon encoding the 18
amino acid sequence which differs in the HSF2 isoforms is indicated (SV), along with the
conserved DNA-binding domain, oligomerization domain (LZ's 1, 2, 3), and carboxyterminal leucine zipper motif (LZ-4).
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Figure 2.11: Schematic representation of HSF2 mRNA alternative splicing.
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Figure 2.12: RT-PCR analysis of HSF2 isoforms during testis development.

RT-PCR analysis of testis expressed HSF2 isoforms during postnatal development. (A)
Total RNA isolated from testes of mice at 7, 14, and 21 days of postnatal development
and from adult mice (6 wk) was analyzed by RT-PCR. (B) The RT-PCR bands from
panel A were quantified and normalized to the S-16 internal control. A refers to adult
mice.
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Figure 2.12: RT-PCR analysis of HSF2 isoforms during testis development.
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Figure 2.13: Reporter gene analysis of HSF2- α and HSF2- β isoforms.

(A) HSF2- α and HSF2- β expression plasmids were cotransfected with an hsp70
promoter-luciferase reporter plasmid into NIH 3T3 cells. Cells were assayed for
luciferase activity and normalized to total protein and luciferase activity from NIH3T3
cells transfected with the reporter gene and parental expression vector. Cell transfected
with HSF2β and HSF2α express 3.6 (±0.5) and 9.6 (±1.1) fold more luciferase
(respectively) than control transfected NIH 3T3 cells. (B) An immunoblot of extracts
from NIH 3T3 cells transfected with the reporter plasmid alone (lane 1), HSF2- β (lane 2),
or HSF2- α (lane 3) was probed with an antibody against HSF2. Relative molecular
weight marker positions are indicated on the left (size in kDa). (C) Gel mobility shift
analysis of extracts from NIH 3T3 cells transfected with the reporter plasmid alone (lane
1), HSF2- β (lane 2), or HSF2- α (lane 3) using an idealized-HSE containing
oligonucleotide as a probe. The position of the HSF2-specific mobility shift (HSF2), a
nonspecific mobility shift (NS) and the free probe (F) are indicated on the left. Calcium
phosphate transfections performed by Dr. Kevin Sarge.
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Figure 2.13: Reporter gene analysis of HSF2- α and HSF2- β isoforms.
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DISCUSSION
HSF1 alternative splicing —implications for differential stress response activation.

These results reveal the existence of a new mechanism for the regulation of HSF1
in mammalian cells. Mouse cells express two distinct HSF1 isoforms, HSF1- α and
HSF1- β, which arise via alternative splicing of the HSF1 pre-mRNA. This alternative
splicing results in the inclusion of a 66 bp exonic sequence which encodes 22 amino
acids not found the in shorter HSF1- β isoform of the protein. This splicing event occurs
immediately carboxy-terminal to the predicted leucine zipper (LZ-4), and inclusion of
this 22 amino acid sequence creates a fifth predicted leucine zipper motif. In addition, the
expression of these two HSF1 isoforms is regulated in a tissue-dependent manner.
We can postulate two possible functions for the regulated expression of the two
HSF1 isoforms. The first possibility is that the additional 22 amino acid sequence
present in the HSF1- α isoform may function to increase the transcriptional activity of the
HSF1 protein, similar to the effect observed for with HSF2 isoforms. Therefore, we
hypothesize that the levels of the HSF1 protein isoforms may be regulated in order to
modulate the potency of the cellular stress response in cells of different tissues.
A second possibility is that the extra 22 amino acids in the HSF1- α protein
functions to modulate the stability of the non-DNA binding form of this HSF1 protein
isoform. As shown above (Figure 10), the insertion of the extra 22 amino acid sequence
in the HSF1- α protein isoform creates a potential fifth leucine zipper motif which
immediately follows the previously identified leucine zipper 4 (Rabindran et al., 1991).
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Leucine zipper 4 has been implicated in the maintenance of HSF1 in the monomeric nonDNA binding form, presumably via interactions with leucine zipper sequences in the Nterminal oligomerization domain. We hypothesize that this fifth leucine zipper may act
in concert with leucine zipper 4 to further stabilize the monomeric non-DNA binding
form of the HSF1- α protein isoform. We further hypothesize that the HSF1- α isoform,
due to the inclusion of this fifth leucine zipper motif, may have an activation temperature
setpoint that is slightly higher than the HSF1- β isoform, which lacks this motif.
Consistent with this, testis, which has an HSF1 activation temperature of 35ºC expresses
predominantly HSF1- β while heart and brain, which have and HSF1 activation
temperature of 42ºC, express predominantly HSF1- α (Sarge et al., 1995a, Sarge et a.l). It
is unlikely, however, that differences in HSF1 isoform expression explain this difference
in HSF1 activation temperature. Cellular environment likely dictates the activation
temperature for HSF1. When drosophila HSF, which is normally activated at 30ºC, is
added to human cell extracts, its set point is reprogrammed to 42ºC, that of the human
HSF1 (Clos et al, 1993 ). Therefore, it is possible that cells express both HSF1- α and
HSF1- β isoforms because together they provide a larger temperature range over which
the cellular stress response can be induced, thus conferring an increased ability to respond
to environmental stresses of differing severity.

HSF2 alternative splici ng—implications for spermatogenic gene regulation.

The results in this work have shown that mice express two distinct protein
isoforms of HSF2 and that these isoforms arise from alternative mRNA splicing. This

77
alternative splicing event results in the inclusion of a 54 bp exon, which encodes an 18
amino acid sequence not found in the HSF2- β isoform. We have shown that this splicing
event is tissue-dependent as well as germ cell type-dependent in the testis. We have also
shown that there is a regulated switch from HSF2- β to HSF2- α during postnatal
development in the mouse testis. Furthermore, we have shown that the inclusion of this
18 amino acid sequence immediately following the carboxy-terminal leucine zipper
(LZ4) has the functional consequence of making the HSF2- α isoform a 2.6 fold more
potent transcriptional activator than the HSF2- β isoform. As both isoforms have similar
DNA binding properties, this effect is likely due to increased transactivating potential.
The most probable explanation for this is that inclusion of the 18 amino acid sequence
causes a more favorable interaction with the transcriptional machinery. This could be by
the addition of a transactivation domain or by favorably affecting the position of an
existing transactivation domain. Previous studies have demonstrated that the
transcription factor cyclic-AMP response element modulator (CREM) is regulated by
alternative splicing during spermatogenesis (Delmas et al., 1993; Foulkes et al., 1992).
CREM switches from transcriptional repressor forms (CREM- α, - β, - γ) to a testis specific
transcriptional activator form (CREM- τ) with the inclusion of two glutamine-rich
transactivation domains (Foulkes et al., 1992).
Previous data from our lab has shown that HSF2 is subject to complex regulation
during spermatogenesis. In the testis, HSF2 expression is upregulated in a cell type,
spermatogenic stage, and developmentally-dependent manner. Additionally, our lab has
shown that unlike in somatic tissues, HSF2 is found in the DNA binding form in the testis
(Sarge et al., 1994). To these complex regulatory regiments, we can now add attenuation
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of HSF2 transcriptional activity by alternative mRNA splicing. HSF2 expressed in testis
cell extracts is capable of binding sequences in the promoter of the hsp70.2 gene, a testisspecific hsp70 family member (Sarge et al., 1994). We, therefore, hypothesize that the
switch from HSF2- β to HSF2- α during spermatogenesis functions to upregulate one or
more hsp genes required to facilitate the unique pattern of protein expression found in
male germ cells. Future studies will be required to identify the cis- and trans-acting
factors involved in the overall upregulation of HSF2 as well as those involved in the
switch in mRNA splicing. Based on the complexity of HSF2 regulation in the testis,
however, these studies are likely to provide insights into the mechanisms of gene
regulation used during spermatogenesis.

Chapter 3
SUMO-1 Modification of HSF2

INTRODUCTION

Biology’s central dogma states that the genetic information of a cell is stored as
DNA. This information is first transcribed or copied to a transient RNA intermediate and
then is translated from RNA into proteins that make up the functional components of the
cell (Alberts et al., 1989). While the concepts imbedded in this central dogma are
inherently correct, they are also greatly over simplified. There are many other levels of
regulation that impinge on the ultimate function of a gene product. One mechanism of
regulation that researchers are finding increasingly important is that of post-translational
protein modification. Examples of this include phosphorylation, proteolytic processing,
glycosylation, covalent lipid modification, and protein coupling (Alberts et al., 1989).
Of interest to this work is post-translational protein coupling, or the covalent
attachment of a polypeptide chain to another protein. The most common example of this
is ubiquitination. Ubiquitin is a 7 kDa polypeptide that is covalently bonded to the εamino group of a lysine residue in the target protein by a multi-enzyme ligase complex
(Hershko and Ciechanover, 1998; Hochstrasser, 1996). The first step involves the
proteolytic processing of ubiquitin to expose a diglycine motif at the C-terminus. The
processed ubiquitin is then covalently attached to a cysteine residue in the E1 or ubiquitin
activating enzyme (Uba1 in S. cerevisiae) in an ATP dependent fashion (Figure 3.1).
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Figure 3.1: Schematic representation of the ubiquitination cycle.

Ubiquitin (Ub) is conjugated to a ubiquitin activating enzyme (E1) in an ATP dependent
fashion. E1 transfers the ubiquitin to one of several ubiquitin conjugating enzymes (E2).
E2 then transfers ubiquitin to a target protein with the assistance of one of many ubiquitin
ligases (E3). This cycle of ubiquitin attachment to a target protein can be repeated
multiple times leading to polyubiquitination and ultimately protein degradation by the
26S proteosome. Degradation of the target protein leads to release of free ubiquitin
which can then be reused in the ubiquitination cycle. (Adapted from Varshavsky, 1997).
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Figure 3.1: Schematic representation of the ubiquitination cycle.
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An E2 or ubiquitin conjugation enzyme then receives the ubiquitin from the E1 in a
transthioesterification reaction. The E2 in conjunction with an E3 or ubiquitin ligase
(often for specificity) catalyzes the transfer of ubiquitin to the target protein in an
amidation reaction. Interestingly, ubiquitin contain several lysine residues
(predominantly Lys-48) which can serve as target residues for further ubiquitination, thus
allowing formation of ubiquitin polymers. This polyubiquitination serves as a targeting
signal for the 26S proteosome and ultimately degradation of the target protein (Hershko
and Ciechanover, 1998; Hochstrasser, 1996; Varshavsky, 1997).
In the past several years, a number of reports have described several proteins with
similarity to ubiquitin. These proteins include Rub1, UCRP, FAU, and SUMO-1
(Mahajan et al., 1997; Matunis et al., 1996; Rao-Naik et al., 1998; Vierstra and Callis,
1999). At least in the cases of Rub1, or its mammalian homolog Nedd8, and SUMO-1,
these seem to be similar but functionally distinct homologs, both with respect to ubiquitin
and each other. Both use ligase complexes discrete from ubiquitin and discrete from each
other (Desterro et al., 1999; Desterro et al., 1997; Gong and Yeh, 1999; Okuma et al.,
1999). In addition, they modify different proteins.
SUMO-1 is a 97 amino acid, 17 kDa polypeptide which shares 18% amino acid
sequence identity with ubiquitin. Originally SUMO-1 was identified as a modifier of the
Ran GTPase activating protein, RanGAP1. It was subsequently and independently
discovered by a number of different laboratories and given an assortment of names—
SUMO-1, UBL1, GMP1, PIC1, Sentrin, Smt3 in S. cerevisiae, and Pmt3P in S. pombe.
SUMO-1 is required for viability (Hodges et al., 1998; Kretz-Remy and Tanguay, 1999;
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Mahajan et al., 1997; Matunis et al., 1996; Saitoh et al., 1997). In S. cerevisiae, Smt3 is
required for entry into the mitotic phase of the cell cycle (Li and Hochstrasser, 1999), and
in S. pombe, PmtP3 is required for control of telomere length and chromosomal
segregation (Tanaka et al., 1999).
SUMO-1 is a member of a family of at least three SUMO proteins in mammalian
cells, named SUMO-1, SUMO-2 and SUMO-3 (Kamitani et al., 1998a; Saitoh and
Hinchey, 2000). SUMO-1 is 48% identical to SUMO-2 and 46% identical to SUMO-3,
while SUMO-2 and SUMO-3 are 95% identical to each other. SUMO-2/3 represent a
larger portion of the SUMO modified proteins in cells than does SUMO-1. In addition, a
large pool of unconjugated SUMO-2/3 exists in cells (Saitoh and Hinchey, 2000).
Interestingly the relative amount of conjugated SUMO-2/3 increases when cells are
exposed to protein damaging stresses such as heat shock, oxidative stress, or the protease
inhibitor MG132 (Saitoh and Hinchey, 2000). SUMO-1 and SUMO-2/3 appear to
colocalize to the same nuclear domain structures, but SUMO 2/3 does not appear to be
conjugated to the predominant SUMO-1 target, RanGAP1 (Saitoh and Hinchey, 2000).
Thus, SUMO-1 and SUMO 2/3 may have some overlap in function, but do represent
functionally distinct members within the SUMO protein family. I will focus on SUMO-1
except where noted.
The tertiary structure for SUMO-1 has been solved and appears to be virtually
superimposable with the structure of ubiquitin. Both ubiquitin and SUMO-1 have a five
β-sheet, two α-helix, ββαββαβ fold (Bayer et al., 1998). A key difference, however, is that

the surface of SUMO-1 contains a groove region that is highly acidic, which ubiquitin
lacks (Bayer et al., 1998). Strikingly, the SUMO-1 binding surface of Ubc9, the SUMO-
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1 conjugating enzyme (E1), has two pockets of highly basic residues that receive the
acidic residues of SUMO-1. Thus this difference in surface charge likely explains how
the conjugating enzymes for SUMO-1 and ubiquitin can discriminate between the two
(Liu et al., 1999).
In addition to structural similarities, SUMO-1 shares other similarities with
ubiquitin. Like ubiquitin, SUMO-1 is translated as a protein that requires proteolytic
processing. SUMO-1 is initially a 101 amino acid peptide that must have four amino
acids at the C-terminus removed to expose a diglycine motif (Matunis et al., 1996;
Matunis et al., 1998). The protease that is responsible for processing SUMO-1 in vivo has
not been definitively identified. One candidate activity has been described in bovine
brain extracts. In an in vitro assay, this 30 kDa activity is capable of processing SUMO-1
to the 97 amino acid form (Suzuki et al., 1999).
SUMO-1 also uses a multi-enzyme ligase complex to attach to target proteins.
The processed SUMO-1 is a substrate for the SUMO E1, which is a heterodimer of two
proteins called SAE1 and SAE2 (for SUMO-1 Activating Enzyme) (Figure 3.2) (Desterro
et al., 1999; Okuma et al., 1999).
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Figure 3.2: Schematic representation of the SUMO-1 modification cycle.

SUMO-1 is covalently attached to the SUMO-1 activating enzyme heterodimer (E1). E1
transfers SUMO-1 to the SUMO-1 conjugating enzyme, Ubc9 (E2). Ubc9 transfers
SUMO-1 directly onto the target protein. Notice how simplified the SUMO-1
modification cycle is relative to the ubiquitination cycle. SUMO-1 uses only one E2 and
no E3. Also, proteins can only be mono-SUMO-1 modified. SUMO-1 modification
functions to alter the function of the target protein rather than to target it for degradation.
Several SUMO-1 specific proteases indicate that the process of SUMO-1 modification is
reversible and that SUMO-1 can be reutilized like ubiquitin. (Adapted from Varshavsky,
1997).
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Figure 3.2: Schematic representation of the SUMO-1 modification cycle.
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SAE1 is homologous to the N-terminus of the ubiquitin E1 and SAE2 shares
homology with the C-terminus of the ubiquitin E1. Cys-173 of SAE2 serves as the
acceptor residue for SUMO-1. Ubc9 is the E2 for SUMO-1. It receives the SUMO-1
from SAE1/2 and transfers it to the target protein (Desterro et al., 1997; Okuma et al.,
1999). All SUMO-1 modified proteins characterized to date interact with Ubc9 directly,
arguing that SUMO-1 may not require a separate E3 ligase for specificity (Duprez et al.,
1999; Kim et al., 1999; Lee et al., 1998; Poukka et al., 1999). Supporting this idea is the
fact that SUMO-1 modification can be reconstituted in vitro with only ATP, SUMO-1,
SAE1, SAE2, Ubc9, and a target protein such as PML or RanGAP1 (Duprez et al., 1999;
Lee et al., 1998).
Initial characterization of SUMO-1 modified proteins was hindered by an activity
that hydrolyzed the SUMO-1 from the modified proteins, suggesting that like ubiquitin
SUMO-1 is a reversible modification. Several proteins with SUMO-1 specific protease
activity have been described. The first sumo-1 specific protease, Ulp1, was identified
from the budding yeast S. cerevisiae and is unrelated to any ubiquitin specific protease.
Ulp1 is capable of hydrolyzing the isopeptide bond from Smt3 (the yeast homolog of
SUMO-1) modified proteins but not from those modified by ubiquitin. Mutations in
Ulp1 cause an accumulation of Smt3 modified proteins and an arrest in the G2 /M phase
of the cell cycle (Li and Hochstrasser, 1999). Recently, the human SENP1 was identified
as a protease that is capable of removing SUMO-1 from modified proteins. SENP1
specifically hydrolyzes the isopeptide bond of SUMO-1 modified proteins, but not
NEDD8 or ubiquitin (Gong et al., 2000). SENP1 is homologous to Ulp1, but not to
ubiquitin specific proteases. Interestingly, SENP1 in vivo appears to selectively remove
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SUMO-1 from nuclear domain proteins like PML and not from RanGAP1 which is
located at the nuclear pore. Presumably this is due to SENP1’s localization within the
nucleus (Gong et al., 2000). Additionally the 30 kDa activity from bovine brain extracts
which is capable of processing SUMO-1 also appears to be a SUMO-1 specific protease
(Suzuki et al., 1999).
SUMO-1 modification of proteins does not appear to target proteins for
degradation. In SUMO-1, the homologous residue to Lys-48 in ubiquitin (required for
polyubiquitination) is a glutamine. No evidence to date has been found for the formation
of SUMO-1 polymers. Consistent with this, SUMO-1 appears to have a number of other
functions in the cell (Hodges et al., 1998; Kretz-Remy and Tanguay, 1999; Saitoh et al.,
1997). For RanGAP-1, SUMO-1 modification is required for localization to the nuclear
pore complex. RanGAP1 is the GTPase activating protein for Ran, a protein involved in
nuclear import. Two species of RanGAP1 exist in the cell, a 70 kDa form and a 90 kDa
form. The 90 kDa form is highly enriched in nuclear extracts and was found to be
SUMO-1 modified (Matunis et al., 1996; Matunis et al., 1998). SUMO-1 modification of
RanGAP1 is required for its association with nup358—also called RanBP—a Ran
binding protein in the nuclear pore complex. Consistent with this finding, SUMO-1
modification of RanGAP1 is required for its association with the nuclear pore complex
(Mahajan et al., 1997; Mahajan et al., 1998; Matunis et al., 1996; Matunis et al., 1998).
For IκB and possibly p53, SUMO-1 modification appears to stabilize these
proteins. NFκB and IκB form a latent or inactivate complex in cells. IκB performs a dual
function in this complex by binding to NFκB to mask its nuclear localization signal and
to inhibit NFκB’s DNA binding and transactivating activity. Upon stimulation (TNFα,
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PMA, etc.) IκBα is phosphorylated on two serine residues (Jaffray et al., 1995; Kroll et
al., 1997). These phosphorylation events trigger and are required for polyubiquitination
of IκB at two lysine residues that ultimately target it for degradation by the 26S
proteosome, leaving NFκB free to dimerize and activate transcription (Jaffray et al.,
1995; Kroll et al., 1997). Recent results have shown that IκBα can also be modified by
SUMO-1 at Lys21, the primary site of ubiquitination. SUMO-1 modification does not
require phosphorylation of IκB. In fact, the serine phosphorylation of IκB required for
ubiquitination appears to inhibit SUMO-1 modification (Desterro et al., 1998). SUMO-1
modified IκB is resistant to TNFα signaling and degradation. Furthermore,
overexpression of Ubc9 or SUMO-1 results in reduced TNFα signaling through NFκB.
Thus, SUMO-1 appears to create a pool of stabilized IκB/NFκB that is resistant to
signaling and protease degradation of IκB (Desterro et al., 1998; Kretz-Remy and
Tanguay, 1999). Like NFκB, p53 is a transcription factor. P53 is unique, however, in
that is has tumor suppressive properties and is integrally tied to programmed cell death.
Normally p53 is made in all cells but is rapidly ubiquitinated and degraded. When cells
are stressed, p53 ceases to be ubiquitinated and is, therefore, stabilized, and p53
accumulates and activates transcription. Recent studies have shown that p53 is also
capable of being SUMO-1 modified (Gostissa et al., 1999; Rodriguez et al., 1999). P53
is SUMO-1 modified at Lys386. Mutations in this residue do not affect the level of
ubiquitination of p53. Modification of p53 by SUMO-1 leads to increased levels of p53
transcriptional activity. Thus SUMO-1 may function to activate or enhance p53’s
transactivating activity (Gostissa et al., 1999; Rodriguez et al., 1999).
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SUMO-1 modification of PML, Sp100, and HIPK-2 causes localization to nuclear
bodies, discrete subdomains within the nucleus. The protein PML was originally
identified through its association with acute promeylocytic leukemia, which in 70-100%
of cases is caused by a translocation event that creates a fusion protein of PML and the
retinoic acid receptor- α (RAR- α). The normal PML, but not the PML-RAR- α fusion
protein is modified by SUMO-1 (Duprez et al., 1999; Kamitani et al., 1998b; Kamitani et
al., 1998c; Muller et al., 1998). PML is normally found in nuclear bodies or ND10,
interchromosomal accumulations of protein. Experiments have demonstrated that
SUMO-1 modification of PML is required for its association into ND10 (Duprez et al.,
1999; Kamitani et al., 1998b; Kamitani et al., 1998c; Muller et al., 1998). A number of
the other ND10 proteins have been identified and include Daxx, BML, RecQ helicase,
and Sp100 (Everett et al., 1999a; Ishov et al., 1999). The ND10 component Sp100 is also
SUMO-1 modified, and SUMO-1 modification is required for Sp100 localization to
ND10 (Sternsdorf et al., 1999). Interestingly, PML plays a critical role in ND10
formation, as cells that lack PML or have a mutant form of PML that cannot be SUMO-1
modified do not form ND10 and the other ND10 proteins localize elsewhere (Ishov et al.,
1999). Thus PML and its SUMO-1 modification are critical for ND10 formation.
Unlike most SUMO-1 modified proteins, PML shows evidence of incrementally
larger products suggesting that PML might be poly-SUMO-1 modified. Experiments
demonstrated, however, that PML is modified by SUMO-1 at three distinct sites, which
explains the appearance of multiple SUMO-1 modified species of PML (Kamitani et al.,
1998b). ND10 formation and both PML and Sp100 SUMO-1 modification appear to be
cell cycle regulated (Everett et al., 1999b). During interphase, both PML and Sp100 are
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SUMO-1 modified and tightly colocalize to ND10. However, during mitosis PML and
Sp100 cease to form ND10 and are no longer SUMO-1 modified. Also, during mitotic
phase a labile, alternatively modified form of PML appears that is stabilized by the
phosphatase inhibitor calyculin A (Everett et al., 1999b). Furthermore, treatment of
interphase cell extracts with calyculin A results in the formation of a PML species with
similar gel mobility as the mitotic phase PML species, suggesting that phosphorylation
may play a role in PML SUMO-1 modification (Everett et al., 1999b).
HIPK2, homeodomain interacting protein kinase 2, is a member of a recently
identified family of nuclear kinases which act as corepressors of homeodomain
transcription factors. HIPK2 is modified at its very carboxy-terminus on lys1182 at a site
that does not match the consensus SUMO-1 modification sequence ( [V/I/L]KX [E/D])
(Kim et al., 1999). Ubc9 interacts with HIPK2 between amino acids 860 and 892. Thus,
HIPK2 has a Ubc9 interaction domain that is discrete from its SUMO-1 modification site.
HIPK2 localizes to discrete nuclear domains. Both the Ubc9 interaction domain and the
SUMO-1 modification site are required for nuclear domain formation. Curiously SUMO1 modified HIPK2 does not co-localize with PML suggesting that the HIPK2 nuclear dots
represent nuclear domains distinct from ND10 (Kim et al., 1999).
In the yeast S. cerevisiae, four proteins known as septins have been shown to be
Smt3 modified. Septins are proteins that are part of the 10 nm fibers that encircle the bud
neck during mitosis. In S. cerevisiae Smt3 is essential for entry into mitosis (Li and
Hochstrasser, 1999). Smt3 conjugated septins appear just before the onset of anaphase
and abruptly disappear during cytokinesis (Johnson and Blobel, 1999). Curiously, only
the septins on the maternal side of the bud neck are Smt3 modified. Smt3 modification
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sites in all four septins have been identified and all conform to the SUMO-1 consensus
sequence. Mutation of these Smt3 sites eliminates almost all the Smt3 staining at the bud
neck and results in a pheontype of defective septin ring disassembly (Johnson and Blobel,
1999). Thus SUMO-1 may play a role in the dynamics of the septin ring in S. cerevisiae.
Previous work has shown HSF1 is posttranslationally modified by
phosphorylation. A great deal of work has gone into characterizing the nature and
function of both the basal and activation induced phosphorylation of HSF1 (Chu et al.,
1996; Cotto et al., 1996; Farkas et al., 1998; Hoj and Jakobsen, 1994; Kim et al., 1997;
Kline and Morimoto, 1997; Knauf et al., 1996; Mivechi and Giaccia, 1995; Xia et al.,
1998; Xia and Voellmy, 1997). In contrast, very little is known about posttranslational
modification of HSF2. Preliminary studies demonstrated that HSF2 did not have the
western blot mobility changes caused by phosphorylation as seen for HSF1 (Sarge et al.,
1993). HSF2 is known to have a relatively short half-life of 60-70 min, and drugs that
inhibit 26S proteosome function such as MG132 and lactacystin lead to the accumulation
and subsequent activation of HSF2. Interestingly, HSF2 does not appear to be ubiquitin
modified (Mathew et al., 1998).
Results from this work indicate that HSF2, but not HSF1 is modified by the
covalent attachment of SUMO-1. HSF2, but not HSF1, is a substrate for SUMO-1
modification in an in vitro conjugation assay. Consistent with these findings, HSF2 but
not HSF1 appears to interact with a portion of Ubc9, the SUMO-1 conjugating enzyme,
in yeast two hybrid assay. The fusion protein GFP-HSF2 colocalizes with SUMO-1 in
nuclear domain structures in approximately 7% of transfected HeLa cells. These data
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would suggest that the function of SUMO-1 modification is to localize HSF2 to nuclear
bodies in a regulated manner.

MATERIALS AND METHODS

Plasmid DNA Construction

The yeast two hybrid vectors pGBD-HSF1 and pGBD-HSF2 were cloned as
previously described (Hong and Sarge, 1999). Polymerase chain reaction (PCR) to was
used to generate BclI sites immediately before and after the open reading frame of the
mouse HSF2β cDNA. The BclI digested PCR fragment of HSF2β was cloned into the
BamHI site of pQE9 (Qiagen, Hilden, Germany), thus generating pQE9-HSF2β. The
pGEX-SUMO-1 plasmid was cloned as previously described, and was a generous gift of
Dr. Joanna Desterro (Desterro et al., 1997).
PCR was used to generate a SalI site and a Kozak consensus sequence (5’CCACC-3’) immediately before and a ClaI site immediately after the open reading frame
of the mouse HSF2β cDNA (Kozak, 1987). This undigested PCR fragment of HSF2β
was cloned into the SmaI site of the pGEM-7Z (Promega, Madison, WI) cloning vector in
which the ClaI site had been destroyed, thus generating the plasmid pGEM-HSF2βSC.
PCR was also used to add an XhoI site and a Kozak consensus sequence before and a
HindIII site, a stop codon, and then a KpnI site immediately before the naturally
occurring stop codon of the open reading frame of mouse HSF1β cDNA. The XhoI and
KpnI digested PCR fragment of HSF1β was cloned into pSP72 (Promega, Madison, WI)
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cloning vector digested with the same restriction endonucleases to generate the plasmid
pSP-HSF1β-XHK.
The plasmid pcDNA-HSF2β-MH6 was cloned by digesting pGEM-HSF2βSC with
SalI and HindIII to liberate the majority of the HSF2 ORF, and cloning it into
pcDNA3.1/MycHisA(-) (Invitrogen, Carlsbad, CA) digested with XhoI and HindIII. The
remaining portion of the HSF2β open reading frame was cloned by PCR using primers
which spanned the endogenous HindIII site in HSF2 and added a HindIII site
immediately 5’ to the endogenous stop codon. The HindIII digested PCR fragment was
cloned into the HindIII site of the previous construct and orientation of the insert was
verified using PCR. The insert for pEGFP-HSF2β was generated by digesting pGEMHSF2βSC with ClaI, filling the resulting ends in with Klenow DNA polymerase (New
England Biolabs, Beverly, MA), and digesting with SalI. The insert was then cloned into
pEGFP-C1 (Clonetec, Palo Alto, CA) digested with SalI and SmaI to create pEGFPHSF2β. pEGFP-HSF1β was cloned by digesting pSP-HSF1β-XHK with XhoI and KpnI
and cloning it into pEGFP-C1 digested with XhoI and KpnI as well.

SUMO-1 Consensus Site Pattern Matching

The SUMO-1 consensus sites were identified in the HSF2 predicted protein
sequence using the PATTERNMATCH algorithm in the Biology Workbench 3.2
program suite. Biology Workbench is a internet based suite of sequence analysis tools
developed by the National Center for Supercomputing Applications at the University of
Illinois and maintained by the San Diego Supercomputer Center
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(http://workbench.sdsc.edu/). The mouse HSF2α protein sequence was analyzed for the
expression [ILV]K. [ED], which searches for either an isoleucine, a leucine, or a valine in
the first position followed by a lysine, any amino acid, and then a glutamate or an
aspartate in last position (Johnson and Blobel, 1999).

Site Directed Mutagenesis of HSF2.

Point mutants were generated in pcDNA-HSF2β-MH6 which change the three
predicted SUMO-1 modified lysine residues to arginine. The predicted residues are Lys
82, Lys 139, and Lys 151. Site directed mutagenesis was performed using the
QuickChange mutagenesis kit (Stratagene, La Jolla, CA) according the manufacture’s
protocol, using the following mutagenic oligonucleotides: HSF2K82R-top, GGAAT
TATCA GACAG GAAAG AGATG G; HSF2K82R-btm, CCATC TCTTT CCTGT
CTGAT AATTC C; HSF2K139R-top, GGTTC AAATA AGACA AGAAA CTATT
GAG; HSF2K139R-btm, CTCAA TAGTT TCTTG TCTTATTTGA ACC; HSF2K151Rtop, GCTTT CAGAA TTAAG AAGTG AGAAT GAATC C; HSF2K151R-btm,
GGATT CATTC TCACT TCTTA ATTCT GAAAG C. The K82R mutant
oligonucleotides were also used to make the K82R mutant in pGBD-HSF2 and pEGFPHSF2β. Mutants were confirmed by DNA sequencing.

Yeast Transformation and the Two-Hybrid Assay.
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A 100 ml culture of YPD medium (20 g/l Bacto peptone (Difco Laboratories,
Livonia, MI), 10 g/l yeast extract (Difco Laboratories, Livonia, MI), 20g/l dextrose, pH
5.8) was inoculated with the S. cerevisiae strain PJ 69-4A (MATa trp 1-901 leu2-3,112
ura3-52 ade2-101 his3-200 gal4∆ gal80∆ LYS2::GAL1-HIS3 GAL2-ADE2 met2::GAL7lacZ) and grown at 30°C with agitation until culture reached OD600 = 1.0 (James et al.,
1996). The yeast were harvested by centrifugation for 5 min at 5,000 x g (5,500 rpm in a
GSA rotor). The supernatant medium was discarded, and the yeast were washed twice in
10 ml TE, pH 7.0 (10 mM Tris-HCl, pH 7.0 + 1 mM EDTA). The yeast were resuspend
in 1 ml of 100 mM LiOAC•TE (100 mM lithium acetate, 10 mM Tris-HCl, pH 7.0 + 1
mM EDTA) and were incubate at 30°C for 1 hr. Cells were then distributed into 100 µl
aliquots. Aliquots were either used immediately or 50 µl of 50% glycerol was added to
each aliquot, and the yeast were stored at -80°C for future transformations. Yeast were
transformed with 5 µg of each plasmid DNA and 50 µg of sheared salmon sperm DNA
(Sigma, St. Louis, MO). The yeast were gently vortexed and incubated at 30°C for 30
min. Four volumes of 40% PEG4000•LiOAC (40% polyethylene glycol (average
molecular weight 3,350 Da—Sigma, St. Louis, MO), 100 mM lithium acetate, 10 mM
Tris-HCl, pH 7.0 + 1 mM EDTA) was added, and the yeast were gently vortexed and
incubated at 30°C for 1 hr. The sample was heat shocked for 5 min at 42°C, and the
yeast were harvested by centrifugation at 6,000 rpm for 1 min. The supernatant was
discarded and the yeast were washed with 1 ml of the appropriate yeast minimal selective
medium (1.7 g/l yeast nitrogen base without amino acids or ammonium sulfate (Difco
Laboratories, Livonia, MI), 5 g/l ammonium sulfate, and 20 g/l dextrose) containing the
appropriate nutrient supplementation to complement the auxotrophies of PJ69-4A
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(typically adenosine, histidine, uracil, and methionine at a concentration of 20 mg/l each),
but lacking the nutrients complemented by the two plasmids of interest (typically leucine
and tryptophan). The yeast were resuspended in 200µl of the appropriate yeast minimal
selective medium and grown on plates containing the same minimal selective medium
(with 20g/l Bacto Agar (Difco Laboratories, Livonia, MI)) at 30ºC for 2-3 days. Colonies
were transferred onto plates that contained the yeast minimal selective medium and also
onto plates that also lacked adenosine or histidine, which is complemented by the twohybrid assay reporter gene. Yeast were again grown 3 days at 30ºC. Growth on the
reporter gene selective plates was interpreted to indicate an interaction between the two
proteins that were expressed from the yeast plasmids.

In vitro SUMO-1 Modification Assay

All in vitro SUMO-1 modifications were done by Dr. Michael J. Matunis as previously
described (Lee et al., 1998).

Recombinant Protein Expression

The bacterial expression plasmid pQE9-HSF2β or pGEX-SUMO1 were
transformed into the E. coli strain BL21 (F- ompT hsdSB (rB- mB- ) gal dcm—Novagen,
Madison, WI) which had been previously transformed with the pREP4 plasmid (Qiagen,
Hilden, Germany) and plated onto LB+Glc plates (10 g/l Bacto tryptone (Difco
Laboratories, Livonia, MI), 5 g/l yeast extract (Difco Laboratories, Livonia, MI), 4 g/l
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dextrose, pH 7.0) containing 100 µg/ml ampicillin and 25 µg/ml kanamycin. Bacteria
were grown overnight at 37ºC. Five colonies were picked from the fresh transformation
plate and pooled for growth overnight at 37ºC with vigorous (>400 rpm) shaking in 5 ml
LB+Glc containing 200 µg/ml ampicillin and 25 µg/ml kanamycin. The overnight culture
was harvested and resuspended in 250 ml fresh LB+Glc containing 200 µg/ml ampicillin
and 25 µg/ml kanamycin. The culture was grown at 37ºC with vigorous shaking to OD595
= 0.6-1.0. The bacteria were harvested and washed once in 30-40 ml M-9 with lactose
medium (48 mM Na2 HPO4 , 22 mM KH2 PO4 , 86 mM g/l NaCl, 187 mM NH4 Cl, 100 µM
CaCl2 , 1mM MgSO4 , 4 g/l D-lactose, 4 g/l casamino acids (Difco Laboratories, Livonia,
MI), 1 mg/l thiamin, 100 µg/ml ampicillin, and 0.5 mM isopropyl- β-Dthiogalactopyranoside). The bacteria were resuspended in 1 l of M-9 with lactose
medium and grown for 3 hr at 37ºC with vigorous shaking to induce protein expression.
Bacteria were harvested by centrifugation and resuspended in 30 ml PBS. The bacteria
were then pelleted and the supernatant was discarded. Bacterial pellets were rapidly
frozen in a dry ice/ethanol bath and stored at –80ºC until needed for protein purification.

Recombinant Protein Purification

Recombinant His6 affinity tagged HSF2 was purified from bacteria containing
pQE9-HSF2β. The bacterial pellet was resuspended in pQE Wash buffer (100 mM KCl,
20 mM Tris-HCl, pH 7.9, 2 mM 2-mercaptoethanol, and 5 mM imidazole). Lysozyme
was added to a final concentration of 100 µg/ml, and the bacteria were incubated for 15
min at room temperature before returning to ice. The bacteria were lysed by sonication
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with three 15 s pulses with a W-220 Sonicator (Mysonix, Farmingdale, NY) with a ½
inch horn at 70% output (~150 W) with cooling on ice for 1 min between pulses.
Sarkosyl was added to 1% (w/v) final concentration and the lysate was cleared by
centrifugation at 12,000 x g for 15 min at 4ºC. The supernatant was applied to a 3 ml
Ni/NTA resin column (Qiagen, Hilden, Germany) at a flow rate of 0.5 ml/min. The
column was washed in pQE wash buffer at a flow rate of 1.5 ml/min until the column
effluent absorbance returned to baseline (measured using an inline 280 nm UV
spectrophotometric detector on a Pharmacia GradiFrac low pressure liquid
chromatography system). The His6 -HSF2 was eluted with an imidazole gradient of 5
mM to 400 mM. The HSF2 protein eluted at 150-200 mM imidazole concentration.
Recombinant glutathione-S-transferase (GST) affinity tagged SUMO-1 was
purified from bacteria containing pGEX-SUMO1. Protein expression was induced as
described in the previous section. The bacterial pellet was resuspended in SUMO lysis
buffer (50 mM Tris-HCl, pH 7.5, 500 mM NaCl, 1mM dithiothreitol). Lysozyme was
added to a final concentration of 100 µg/ml, and the bacteria were incubated for 15 min at
room temperature before returning to ice. The bacteria were lysed by sonication with
three 15 s pulses with a W-220 Sonicator (Mysonix, Farmingdale, NY) with a ½ inch
horn at 70% output (~150 W) with cooling on ice for 1 min between pulses. Triton X100 was added to 1% (w/v) final concentration and the lysate was cleared by
centrifugation at 12,000 x g for 15 min at 4ºC. The supernatant was applied to 750 µl of a
50% slurry of glutathione agarose resin (Sigma, St. Louis, MO) in SUMO lysis buffer.
The slurry was incubated at 4ºC for 20 min with constant inversion mixing. The resin
was collected by centrifugation and the supernatant was discarded. The resin was washed
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five times with 1 ml SUMO lysis buffer. The protein was eluted twice by incubation
with 250 µl SUMO lysis buffer with 10 mM glutathione for 2 min. It is necessary to
adjust the pH to 7-7.5 with NaOH before using the elution buffer, as glutathione is
supplied as a free acid and dramatically lowers the pH of the buffer (to around pH 3).
The eluates were pooled. More than 50% of the SUMO-1 remained bound to the resin.
Incubation with elution buffer for more than 2 hr resulted in the elution of the majority of
the bound SUMO-1.
Both His6 -HSF2 and GST-SUMO-1 were dialyzed into a buffer containing 20
mM Tris, pH 7.5, 100 mM KCl, 2 mM 2-mercaptoethanol, and 10% glycerol. The
concentration of the protein was determined using the BioRad Protein Assay Kit
(BioRad, Hercules, CA). All measurements were normalized to a BSA standard
concentration curve. The proteins were aliquotted and rapidly frozen in a dry ice/ethanol
bath before storing at –80ºC until needed.

Transient Transfection of HeLa Cells

HeLa cells were transfected with pEGFP-C1, pEGFP-HSF1β, or pEGFP-HSF2β
independently using Lipofectamine 2000 (Life Technologies, Rockville, MD). In brief,
HeLa cells were seeded in a six-well tissue plate with a sterile nitric acid washed 22mm x
22mm cover slip, such that the cells would be approximately 80% confluent by the
following morning. HeLa cells were grown in DMEM containing 10% fetal bovine
serum (FBS) and 50 µg/ml gentamicin (Life Technologies, Rockville, MD) at 37ºC with
5% CO2 . For each transfection, 4 µg of DNA was mixed with 250 µl of DMEM without
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FBS or antibiotics in one well of a 24 well tissue culture dish. In a second well, 7.5 µl of
Lipofectamine 2000 was mixed with 250 µl of DMEM and incubated for 3 min at room
temperature. The two mixtures were then combined and allowed to incubate for 20 min
at room temperature. The medium was removed from the HeLa cells. The HeLa cells
were washed once with 2.5 ml of DMEM without FBS or antibiotics and 500 µl of
DMEM without FBS or antibiotics was added to cells. The DNA/Lipofectamine mixture
as then added to the HeLa cells and incubated for 6 hr at 37ºC with 5% CO2 . After six
hours, the DNA containing DMEM was removed and the media was replaced with 3 ml
DMEM containing 10% FBS and 50 µg/ml gentamicin. HeLa cells were grown for 24 hr
before analyzing by fluorescence microscopy.

Immunofluorescent Microscopy

HeLa cells were plated on 22x22mm nitric acid washed coverslips in 6 well
dishes 24h before transfecting or doing microscopy. The coverslips were removed from
6 well dish and fixed with cold (-80ºC) MeOH for 6 min. The SUMO-1 primary
monoclonal antibody 21C7 or the antibody and 250 µg of purified pGEX-SUMO1 protein
for the preadsorbed control was diluted 1:1000 in phosphate buffered saline (PBS) [137
mM NaCl, 2.7 mM KCl, 8 mM Na2 HPO4 , 1.5 mM KH2 PO4 ] +2% bovine serum albumin
(BSA—Fraction V, Sigma, St. Louis, MO). The antibody dilutions were incubated 20
min on ice and centrifuged for 10 min at 12,000 rpm at room temperature. The
supernatant of the antibody dilutions was retained. The coverslips were removed from the
MeOH and cells were rehydrated for 30s in PBS. The coverslips were washed three
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times in PBS and 3 times in PBS+2%BSA. The coverslips were incubated with the
antibody dilution or the preadsorbed antibody for 20 min at room temperature. The
coverslips were washed three times with PBS+2%BSA. The coverslips were incubated
20 min with a 1:200 dilution of a horse anti mouse IgG antibody conjugated to the Texas
Red fluorochrome (Vector Labs, Burlingame, CA). The coverslips were then washed
three times PBS+2%BSA and three times with PBS. The coverslips were incubated 5
min with 50 ng/ml 4`,6-diamidino-2-phenylindole (DAPI). Coverslips were washed three
times briefly in distilled water and the excess moisture was removed. Coverslips were
mounted on a slide with Vectashield (Vector Labs, Burlingame, CA) mounting medium
and sealed using blue fingernail polish. Immunostaining was visualized using a Nikon
fluorescent microscope with a 60x objective and a Nikon Spotcam digital-imaging
camera.

RESULTS

Two Hybrid Analysis of the HSF2/Ubc9 interaction

The yeast two-hybrid system, developed by Fields and Song in 1989, is a
sensitive method for identifying protein-protein interactions. This system can be used to
demonstrate interactions between known proteins or for identifying unknown factors that
interact with a given protein (Fields and Song, 1989). The yeast two hybrid system relies
on the observation that eukaryotic transcription factors are often modular. The DNA
binding domain is separate from the transactivation domain in many transcription factors
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including the yeast GAL4 transcription factor. Protein-protein interactions can be
demonstrated by creating a fusion protein of one protein to the activation domain (the
target) and a fusion protein of another protein to the DNA binding domain (the bait)
(Figure 3.3). By transforming these constructs into a yeast cell which contain a reporter
gene under the control of the appropriate promoter element (as dictated by the DNA
binding domain), interactions can be demonstrated by the activity of the reporter gene. If
the proteins of interest interact, the activation and DNA binding domain will be held in
close enough proximity by the protein-protein interactions to activate transcription of the
reporter gene. If the proteins fail to interact, the reporter gene will remain silent, because
the activation domain will not be in the proximity of the DNA binding domain(Reviewed
in (Bartel et al., 1993; Bartel and Fields, 1995; Fields and Sternglanz, 1994; Mendelsohn
and Brent, 1994)).
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Figure 3.3: Schemat ic diagram of the yeast two hybrid assay.

Plasmids that express a “bait” protein (HSF2) fused to a DNA binding domain and a
“target” protein (Ubc9) fused to a transcriptional activation domain are transformed into a
yeast strain with a reporter gene (typically a gene to compliment an amino acid
auxotrophy) under the control of a promoter containing a binding element for the bait
plasmid DNA binding domain. If the bait and target proteins interact, the activation
domain and DNA binding domain are held in close proximity, and transcription of the
reporter gene is activated, allowing the yeast to grow on medium lacking the amino acid
produced by the reporter gene. If the bait and target proteins do not interact, the
activation and DNA binding domains are not tethered and cannot activate transcription of
the reporter gene. The reporter gene remains silent and the yeast are unable to grow on
reporter gene selective medium.
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Figure 3.3: Schematic diagram of the yeast two hybrid assay.
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Initially Fields and Song used the yeast two-hybrid system to demonstrate the
interaction between SNF1, a kinase, and SNF4, an SNF1 associated protein (Fields and
Song, 1989). Later this technique was used to identify unknown proteins that interact
with a given protein by screening a cDNA library in which the cDNA clones were fused
to an activation domain (Chien et al., 1991). This library screening technique was how a
large portion of Ubc9 (a region corresponding to amino acids 4-128 of Ubc9’s 160 amino
acids) was identified as a rat estrogen receptor- β (ER- β) (In, Y., data not shown).
Serendipitously (and erroneously) HSF2 was used a negative control for interaction with
Ubc9. To demonstrate that HSF2 interacted with Ubc9 specifically, we tested whether
the partial Ubc9 protein (pVP16∆Ubc9) could interact with HSF1 (pGBD-HSF1) or the
Gal4 DNA binding domain alone (pGBD-C2) as well as with HSF2 (pGBD-HSF2)
(Figure 3.4). Ubc9 interacts with HSF2 and perhaps only weakly with HSF1 in the yeast
two-hybrid assay. The interaction with HSF1 must be considered suspect because
pGBD-HSF1 has demonstrated a certain inherent transcriptional activity which manifests
itself as very weak growth under selective conditions without an appropriate activation
domain partner. Ubc9 is not capable of interacting with the Gal4 DNA binding domain
alone, suggesting that Ubc9 does interact with HSF2 specifically.

In vitro SUMO-1 modification of HSF2.

All SUMO-1 modified proteins identified to date have also interacted with Ubc9. This
observation prompted us speculate that HSF2 might be SUMO-1 modified. To this end,
in vitro transcribed and translated HSF2 was used as a substrate in an in vitro SUMO-1
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modification assay. HSF2 was transcribed from a full-length cDNA (including
untranslated regions) of the mouse HSF2- β gene (called c9) (Sarge et al., 1991). The in
vitro transcribed mRNA was translated in the presence of 35 S-methionine to produce
radiolabeled HSF2 protein. The in vitro SUMO-1 modification system contains purified
recombinant SUMO-1 and Ubc9, a HeLa cell extract, which contains the SUMO
activating enzyme activity of the SAE1/2 heterodimer, ATP, and an ATP regenerating
system. When the HSF2 protein is incubated with the HeLa extracts alone, a faint higher
molecular weight protein corresponding in size to the SUMO-1 modified form of HSF2
appears (Figure 3.5). This is presumably due to small amounts of endogenous SUMO-1
and Ubc9 in the HeLa extracts. When either SUMO-1 or Ubc9 are omitted from the
reaction only the faint SUMO-1 modified HSF2 product is observed. Interestingly the
abundance of this product decreases when only Ubc9 is added to the reaction mix,
presumably due to competition for the endogenous SUMO-1. When SUMO-1 and Ubc9
are added to the reaction mixture, a substantial increase in the higher molecular weight
product is observed, corresponding to SUMO-1 modified HSF2 (Figure 3.5).
Interestingly HSF2 also appears to be a substrate for SUMO-2 modification as well as
SUMO-1 modification. In contrast, HSF1 does not appear to be a substrate for SUMO-1
modification (Figure 3.6). When in vitro translated HSF1 is incubated in the presence of
the HeLa cell lysate, several higher molecular weight products are observed. However,
when Ubc9 or SUMO-1 or both are added to the reaction, the abundance or mobility of
these is not affected. HSF1, therefore, does not appear to be a substrate for SUMO-1
modification in vitro. The higher molecular weight products observed in the presence of
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the HeLa cell lysates are most likely hyperphosphorylation states commonly observed
with HSF1 (Sarge et al., 1993).

Nuclear colocalization of SUMO-1 and GFP-HSF2.

One functional consequence of SUMO-1 modification often observed is localization to
discrete nuclear domain structures. This appears to be the case for the SUMO-1 modified
forms of HIPK2, PML, and Sp100 (Kretz-Remy and Tanguay, 1999). We were
interested in determining if HSF2 was localized to nuclear domain structures with
SUMO-1. Initial attempts to use a rabbit polyclonal antiserum for colocalization
experiments were unsuccessful due to high nonspecific background staining (data not
shown). To solve this problem, plasmids for expressing a fusion protein of the jellyfish
Aequorea victoria green fluorescent protein (GFP) and either HSF1- β or HSF2- β were
developed. The human cervical carcinoma cell line HeLa was transfected with pEFGPHSF2β and then fixed and stained with a monoclonal antibody against SUMO-1 (21C7)
as well as DAPI for visualization of the nucleus (Figure 3.7). Only a few of the cells that
were transfected with pEGFP-HSF2β had the punctate nuclear GFP-HSF2 staining
observed with nuclear bodies. The majority of the cells had cytosolic staining in which
GFP-HSF2 was excluded from the nucleus. Of those cells that did contain GFP-HSF2
nuclear domain staining, the HSF2 nuclear domain structures did colocalize with SUMO1.
To verify that the punctate nuclear staining was specific to HSF2, HeLa cells were
transfected with pEGFP-C1 (the parental GFP expression vector), pEGFP-HSF1β, or
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pEGFP-HSF2β. The staining pattern observed for GFP-HSF2 is distinct from either
GFP-HSF1 or GFP alone (Figure 3.8). GFP is expressed throughout the cytosol and the
nucleus, whereas GFP-HSF1 is localized almost entirely within the nucleus. Neither GFP
nor GFP-HSF1 display the punctate nuclear staining or the predominantly cytosolic
staining patterns observed with HSF2.
In order to establish that the protein staining by the SUMO-1 antibody was
specific for SUMO-1, purified His6 -HSF2β and GST-SUMO-1 were purified (Figure
3.9). The purified The SUMO-1 antibody was preincubated with 2% BSA or 2% BSA
containing 250 µg of purified GST-SUMO-1 prior to staining pEGFP-HSF2β transfected
HeLa cells. Preadsorbing the SUMO-1 antibody with SUMO-1 prior to staining
completely abolished the nuclear domain structure staining normally observed with
SUMO-1 (Figure 3.10). Preadsorbing the antibody with 250 µg of His6 HSF2 protein had
no effect on SUMO-1 antibody staining (data not shown).
Preliminary efforts at coimmunoprecipitating SUMO-1 with HSF2 were not
successful. In fact, observing an HSF2 immunoreactive species of the appropriate size
for SUMO-1 modified HSF2 was not possible either (data not shown). This is
presumably due to the small percentage of cells that contain SUMO-1 modified HSF2
and the small portion of HSF2 within those cells that is SUMO-1 modified. We
suspected that SUMO-1 modification of HSF2 might be cell cycle regulated. To test this,
we stained cells with the nonvital DNA stain Hoescht 33342 (bisbenzimide) and the
calcium channel inhibitor Verapamil (to prevent the rapid efflux of the Hoescht stain
from the cells), and sorted them according to cell cycle stage using a fluorescentactivated cell sorter (FACS) (Krishan, 1987). These sorted cells were used for HSF2
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immunoblot analysis and for HSF2 immunoprecipitation followed by SUMO-1
immunoblot analysis (data not shown). Neither of these analyses was successful in
detecting a SUMO-1 modified HSF2 product. These results do not necessarily indicate
that SUMO-1 modification of HSF2 is not cell cycle regulated. If SUMO-1 modification
of HSF2 is adversely affected by the drug Verapamil or only occurs in a small portion of
the cells in one of the sorted populations, immunoblot analysis may still fail to detect the
SUMO-1 modified HSF2 product.
As only a few cells seemed to contain punctate GFP-HSF2 nuclear staining, we
were interested in quantifying the percentage of cells the HSF2 nuclear domain staining.
The results from two experiments are shown in Table 1.

Table 1. Quantification of GFP-HSF2 nuclear domain staining
GFP-HSF2
Pos. Cells
422
412

Nuclear Dots
27
30

%
Nuclear Dots
6.4 %
7.3 %

Cells that were positive for GFP-HSF2 staining were
simultaneously counted with GFP-HSF2 positive cells
that contained punctate nuclear staining (Nuclear Dots).

These data indicate that only 6.8% (±0.4) of the GFP-HSF2 positive HeLa cells contain
punctate nuclear domain structures.

Identification of the SUMO-1 modification site in H SF2.
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We were interested in determining which amino acid residue or residues were
modified by SUMO-1 in HSF2. The mouse HSF2- α protein contains 36 lysine
residues—too many to mutate and analyze individually (Sarge et al., 1991). However, of
the SUMO-1 modified proteins described to date, all but HIPK2 conform to a consensus
modification site of isoleucine, leucine, or valine followed by the SUMO-1 modified
lysine, any amino acid and finally a glutamate or aspartate residue (Johnson and Blobel,
1999). We analyzed the mouse HSF2- α sequence to determine if there were consensus
SUMO-1 modification stites. This analysis was done using the PATTERNMATCH
algorithm from the Biology Workbench 3.2 suite of sequence analysis tools. HSF2
contains three SUMO-1 consensus modification sites at lys82, lys139, and lys151 (Figure
3.11) (Sarge et al., 1991).
Mutations were made in pcDNA-HSF2β-MH6 that changed each of these lysine
residues to arginine—K82R, K139R, and K151R. The plasmid pcDNA-HSF2β-MH6 was
chosen because in addition to being an epitope tagged mammalian expression vector,
which could be useful in future research, it contains a T7 RNA polymerase promoter
suitable for in vitro transcription and translation. All three mutations and the wild type
pcDNA-HSF2β-MH6 were used as substrates for in vitro SUMO-1 modification reactions
(Figure 3.12). The results of this clearly indicate that lysine 82 is the primary site of
SUMO-1 modification on HSF2. The consensus SUMO-1 modification site found at
Lys82 in the mouse HSF2 is conserved in the chicken and human homologs HSF2,
suggesting that SUMO-1 modification of HSF2 may be conserved among vertebrates
(Schuetz et al., 1991).
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Figure 3.4: Two-hybrid analysis of the HSF2/Ubc9 interaction.

Ubc9 interacts with HSF2 (pGBD-HSF2+pVP16∆Ubc9) and only weakly with HSF1
(pGBD-HSF2+pVP16∆Ubc9). HSF1 and HSF2 do not interact with the VP16 activation
domain alone (pGBD-HSF1+pVP16 and pGBD-HSF2+pVP16), and Ubc9 does not
interact with the Gal4 DNA binding domain alone (pGBD-C2+ pVP16∆Ubc9). PR65 is a
positive control that is know to interact with HSF2 (pGBD-HSF2 + pGAD-PR65).
Medium lacking tryptophan (-trp) and leucine (-leu) selects for both plasmids. Media
lacking adenosine (-ade) or histidine (-his) are selective for two reporter genes in the S.
cerevisiae strain PJ69-4A.
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Figure 3.4: Two-hybrid analysis of the HSF2/Ubc9 interaction.
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Figure 3.5: In vitro SUMO-1 and SUMO-2 modification of HSF2.

HSF2 is a substrate for both SUMO-1 and SUMO-2 modification. Modification requires
the addition of HeLa cytosol (SUMO activating enzyme activity), Ubc9, and SUMO-1 or
SUMO-2. Omission of any of these results in a dramatic diminution of the abundance of
SUMO modified HSF2 (dark triangle). The unmodified HSF2 is indicated by the light
triangle. In vitro modification reactions containing 35 S-labeled HSF2 are analyzed by
SDS-PAGE and visualized by autoradiography. In vitro SUMO-1 modification assay
performed by Dr. Michael J. Matunis.
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Figure 3.5: In vitro SUMO-1 and SUMO-2 modification of HSF2.
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Figure 3.6: In vitro SUMO-1 modification analysis of HSF1.

In vitro translated HSF1 protein is used as substrate in an in vitro SUMO-1 modification
reaction. Addition of HeLa cytosol results in the appearance of several higher molecular
weight products. The addition of SUMO-1 or Ubc9 or both does not affect the
abundance or migration of these products, indicating that HFS1 is not a substrate for
SUMO-1 modification in vitro. The higher molecular weight HSF1 products are likely
the hyperphosphorylated states often observed with HSF1. By comparison HSF2 is a
substrate for SUMO-1 modification. In vitro SUMO-1 modification assay performed by
Dr. Michael J. Matunis.
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Figure 3.6: In vitro SUMO-1 modification analysis of HSF1.
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Figure 3.7: Colocalization of GSP -HSF2 and SUMO-1.

Transiently transfected HeLa cells expressing GFP-HSF2 were stained with an antibody
against SUMO-1 and DAPI for nuclear staining. Shown are the GFP-HSF2 (green),
SUMO-1 (red), and DAPI (blue) staining from three representative fields of cells. GFPHSF2 and SUMO-1 colocalize (GFP-HSF2 + SUMO-1) in discrete domains (seen as
yellow dots) with the nucleus (GFP-HSF2 + DAPI).

119
Figure 3.7: Colocalization of GSP -HSF2 and SUMO-1.
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Figure 3.8: Unique localization of GFP-HSF2.

Transiently transfected HeLa cells expressing GFP, GFP-HSF1, or GFP-HSF2 were
visualized by fluorescent microscopy. Two fields of cells are shown for each. GFP is
expressed throughout the cytosol and nucleus. GFP-HSF1 expression is almost entirely
confined to the nucleus. GFP-HSF2 is expressed predominantly in the cytosol with very
little nuclear staining except for cells with nuclear domain staining.
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Figure 3.8: Unique localization of GFP-HSF2.
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Figure 3.9: Purification of recombinant HSF2 and SUMO-1.

Cleared bacterial lysates (Extract) from bacteria expressing either His 6 HSF2 or GSTSUMO-1 and purified eluate from the Ni/NTA agarose or glutathione agarose resins
respectively (Eluate) were analyzed by SDS-PAGE and visualized by Coomassie
staining.
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Figure 3.9: Purification of recombinant HSF2 and SUMO-1.
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Figure 3.10: Preadsorbed control for SUMO-1 Immunofluorescent Staining.

HeLa cells transiently expressing GFP-HSF2 were stained with an antibody to SUMO-1
or an antibody to SUMO-1 that had been preadsorbed to 250 µg of purified GST-SUMO1. Preadsorbing the SUMO-1 antibody with GST-SUMO-1 completely abolishes
SUMO-1 nuclear domain staining.
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Figure 3.10: Preadsorbed control for SUMO-1 Immunofluorescent Staining.
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Figure 3.11: Consensus SUMO-1 modification site analysis of HSF2.

The mouse HSF2- α protein sequences was analyzed for the consensus SUMO-1
modification site sequence (isoleucine, leucine, or valine followed by lysine, any amino
acid and finally a glutamate or aspartate residue). The analysis was performed using the
PATTERNMATCH algorithm from Biology Workbench 3.2. HSF2 contains three
consensus modification sites (indicated with bolded/underlined text) at lys82, lys139 and
lys151. The 18 amino acids of the HSF2- α specific exon (amino acids 391-409) are
italicized.
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Figure 3.11: Consensus SUMO-1 modification site analysis of HSF2.

PATTERNMATCH analysis of mHSF2α with [IVL]K. [ED]

MKQSSNVPAF LSKLWTLVEE THTNEFITWS QNGQSFLVLD EQRFAKEILP
KYFKHNNMAS FVRQLNMYGF RKVVHIESGI IKQERDGPVE FQHPYFKQGQ
DDLLENIKRK VSSSKPEENK IRQEDLTKII SSAQKVQIKQ ETIESRLSEL
KSENESLWKE VSELRAKHAQ QQQVIRKIVQ FIVTLVQNNQ LVSLKRKRPL
LLNTNGAPKK NLYQHIVKEP TDNHHHKVPH SRTEGLKSRE RISDDIIIYD
VTDDNVDEEN IPVIPETNED VVVDSSNQYP DIVIVEDDNE DEYAPVIQSG
EQSEPAREPL RVGSAGSSSP LMSSAVQLNG SSSLTSEDPV TMMDSILNDN
INLLGKVELL DYLDSIDCSL EDFQAMLSGR QFSIDPDLLV DLFTSSVQMN
PTDNINNTKS ENKGLEATKS SVVQHVSEEG RKSKSKPDKQ LIQYTAFPLL
AFLDGNSASA IEQGSTTASS EVVPSVDKPI EVDELLDSSL DPEPTQSKLV
RLEPLTEAEA SEATLFYLCE LAPAPLDSDM PLLDS
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Figure 3.12: In vitro modification analysis of HSF2 mutants.

In vitro translated pcDNA-HSF2β-MH6 (WT) and the SUMO-1 consensus site mutants
K82R, K139R, and K151R were used as substrates in in vitro SUMO-1 modification
reactions. The K82R mutation abolishes the majority of the SUMO-1 modification on
HSF2. In vitro SUMO-1 modification assay performed by Dr. Michael J. Matunis.
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Figure 3.12: In vitro modification analysis of HSF2 mutants.
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DISCUSSION
In this work we have demonstrated that in vitro translated HSF2, but not HSF1 is
a substrate for SUMO-1 and SUMO-2 modification in vitro. Consistent with this, we
have demonstrated that HSF2 can interact with a portion of Ubc9, the SUMO-1
conjugating enzyme, in a two-hybrid assay. We have also shown that GFP-HSF2
colocalizes with SUMO-1 in discrete nuclear domain structures in 7% of GFP-HSF2
expressing HeLa cells. Finally, we have shown that lysine 82 is the primary site of
SUMO-1 modification in vitro.
These data suggest that the role of SUMO-1 modification of HSF2 is to target
HSF2 to discrete nuclear domain structures. HSF2 nuclear dots have been observed
previously (Sarge et al., 1993). These data provide a likely explanation for this
observation. Examination of the localization of the GFP-HSF2(K82R) mutant should
demonstrate whether this is the case. SUMO-1 modification causes several other proteins
to become localized into nuclear domains. PML and Sp100 both localize to the same
nuclear domain, ND10, while HIPK2 appears to form a second class of SUMO-1
containing nuclear domains (Duprez et al., 1999; Kim et al., 1999; Muller et al., 1998;
Sternsdorf et al., 1999). Determining whether HSF2 colocalizes to one of these two
nuclear domains or a novel nuclear domain will be important for determining the function
of HSF2/SUMO-1 modification.
Interestingly, HSF2 is able to interact with a portion of HSF2 that contains over
75% of the full length Ubc9 protein, but cannot interact with full-length Ubc9 in the yeast
two-hybrid assay. This observation could be an artifact due to the nature of both
constructs. The partial Ubc9 construct is fused to the VP16 activation domain while full-
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length Ubc9 construct is fused to the Gal4 activation domain. If, however, it is not an
artifact, this would suggest that there are domains at either the very amino-terminus or
the very carboxy-terminus of Ubc9 that regulate its interaction with HSF2. Further
characterization of the domains in HSF2 and Ubc9 required for interaction may lead to
insights into how SUMO-1 modification of HSF2 is regulated.
Interestingly, in vivo very little of the total HSF2 is SUMO-1 modified, but in
vitro a large portion of HSF2 can by modified by SUMO-1. This would suggest that
either a positive regulation event, such as phosphorylation of HSF2, occurs
inappropriately in the in vitro modification assay, or a negative regulator of SUMO-1
modification of HSF2 is not present in the in vitro assay system. Negative regulators
could include some modification of HSF2 itself or perhaps some protein that interacts
with HSF2 to prevent SUMO-1 modification.
Understanding the events that regulate SUMO-1 modification will likely provide
insights into the function of SUMO-1 modified HSF2 and ultimately into the general
functions of both SUMO-1 and HSF2.

Chapter 4
Discussion and Future Directions
The results in this work present two novel ways in which the activity of HSFs are
regulated. Both HSF1 and HSF2 undergo alternative splicing which gives rise to two
protein isoforms for each. These alternative slicing events are regulated in a tissue
dependent manner. In addition HSF2 alternative splicing within the testis is regulated in
a germ cell type and developmental manner. HSF2, and not HSF1, is modified by the
conjugation of the SUMO-1 protein to lysine 82 in approximately 7% of HeLa cells
transiently expressing GFP-HSF2. The regulatory mechanism for SUMO-1 modification
is not understood, though it appears as a consequence of SUMO-1 modification HSF2
becomes localized to nuclear domain structures.
The overall question that arises from these results is what are the functions of
these modifications. What is the functional difference between HSF1- α and HSF1- β?
What is the functional difference between HSF2- α and HSF2- β? What is the function of
HSF2 localization to nuclear domains? What is the function of HSF2 in the cell? These
are all important questions that will undoubtedly require a great deal of further research
to understand. A few experiments to begin addressing these questions readily come to
mind, however.

THE FUNCTIONAL DIFFERENCE BETWEEN HSF1-α AND HSF1-β .
Recently, we have obtained a full-length mouse HSF1- α expression plasmid. This
construct could be used to determine if there are differences in the ability of HSF1- α and
HSF1- β to activate gene transcription similar to those observed from HSF2. Also the
132
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creation of an antibody specific to HSF1- α would make it possible to test if different
stress conditions resulted in differential activation of HSF1- α verses HSF1- β. This would
address the hypothesis that the isoforms function either to modulate the activation
temperature or to broaden the temperature range over which the stress response can be
activated.

THE POSSIBILITY OF STRESS INDUCED SUMO MODIFICATION OF HSF1.
The data from this work would suggest that HSF1 is not a substrate for SUMO-1
modification. Recent data however indicate that HSF1 forms nuclear granules upon
activation by stress such as heat shock or cadmium treatment (Cotto et al., 1997). In
addition, overall SUMO-2/3 conjugation is induced upon exposure of cells to stress such
as those that cause HSF1 to become activate and to form nuclear granules (Saitoh and
Hinchey, 2000). Taken together, these data suggest that HSF1 might be a substrate for
SUMO modification under stress conditions. HSF1 that is in vitro translated does not
bind to DNA suggesting that it is not in the active state, and therefore would not likely be
a substrate for SUMO modification in vitro unless it was first activated by heat shock or
some other stressful treatment. Further data indicates that HSF1 activated by treatment
with 20 mM salycilate does not form nuclear granules even though it has been activated
and can bind to DNA (Cotto et al., 1997). Previous work has shown that salycilate
treatment does not induce the phosphorylation changes seen in HSF1 activated by other
stresses (Cotto et al., 1996; Jurivich et al., 1995; Jurivich et al., 1992). This would
suggest that a change in phosphorylation might be the regulatory event that is required for
SUMO-1 or –2/3 modification of HSF1.
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THE ROLE OF HSF2-α AND HSF2-β IN SPERMATOGENESIS.
Recent conflicting data may require us to reexamine our thinking about the role of
HSF2 and the HSF2 isoforms in spermatogenesis. A recent paper indicates that HSF2 is
not activated during spermatogenesis in rats, as it is for mice (Alastalo et al., 1998).
Also, the data indicates that expression of hsp70 does not correlate with HSF2 expression
during spermatogenesis (Alastalo et al., 1998). At least preliminarily HSF2 does not
appear to be functioning to regulate the expression of hsps during spermatogenesis.
Interestingly, this same work showed that HSF2 is localized to intracellular bridges in
germ cells from zygotene spermatocytes through mature spermatozoa (Alastalo et al.,
1998). The function of this HSF2 is not known. Initially we proposed that the increase
in HSF2- α expression was to increase the amount of hsps and other HSF2 regulated
proteins expressed during spermatogenesis. More research will be needed to understand
the function of HSF2 and the HSF2 isoforms in the testis.

OTHER FUNCTIONS OF HSF2
Other than in testis, HSF2 is not found in the DNA binding form in any other
tissue in adult mammals even though HSF2 is found in every tissue. This begs the
question of what is function of HSF2. Recent data from our lab demonstrated that HSF2
interacts stably with PR65, a regulatory subunit of protein phosphatase 2A (PP2A) (Hong
and Sarge, 1999). Interestingly HSF2 interacts with PR65 in the absence of the
phosphatase catalytic subunit. The function of this interaction is not clear. Preliminary
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efforts to determine if HSF2 functions to regulate PP2A activity by sequestering PR65
were inconclusive (Hong and Sarge, 1999). In preliminary experiments, however, PR65
colocalizes with GFP-HSF2 in nuclear domain structures, suggesting that PR65 can
interact with SUMO-1 modified HSF2 (Y. Hong, data not shown). PR65 can, and clearly
does, interact with unmodified HSF2 as well. Perhaps the function of the HSF2/SUMO-1
modification is to recruit PR65 to nuclear domains, though the functional consequence of
this happening is not known.

THE REGULATION OF THE SUMO-1 MODIFICATION OF HSF2.
It is clear that to understand the function of SUMO-1 modification of HSF2 we
must first understand its regulation. There are two regulatory events that need to be
addressed. First is the issue of only certain cells containing SUMO-1 modified HSF2 in
GFP-HSF2 transfection assays, and the second is the issue of only some of the HSF2 in a
cell being SUMO-1 modified. Perhaps SUMO-1 modification of HSF2 is cells cycle
regulated. The most direct way of examining this would be using immunofluorescence
microscopy to visualize the HSF2 domain structures. Cell cycle regulation could be
tested using synchronized cells harvested at different time points during the cell cycle or
by using cell cycle sorted cells deposited onto slides. These experiments would require
an antibody against HSF2 that lacked nonspecific background staining.
Also, understanding the events within the cell that regulate SUMO-1 modification
of HSF2 will be critical to our overall understanding of SUMO-1 modification of HSF2.
It is likely that some modification of HSF2 could be the regulatory event required for
SUMO-1 modification of HS2. Therefore, a basic understanding of how HSF2 is
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modified is critical. Previous data indicates that HFS2 may be modified by the covalent
attachment of O-linked N-acetylglucosamine to serine and threonine residues (data not
shown). This modification is reciprocal with serine/threonine phosphorylation in certain
cases (Hart, 1997; Jackson and Tjian, 1988; Kelly et al., 1993; Reason et al., 1992).
Other modifications to examine might include methylation, acetylation, or even
ubiquitination.

THE 26S PROTEOSOME AND SUMO MODIFICATION OF HSF2.
Recent studies indicate that HSF2 can be activated in cells treated with the drugs
MG132 or lactacystin, which function to inhibit 26S proteosome function, or in ts85 cells
which have a temperature sensitive mutation in the ubiquitin conjugating enzyme (E1)
gene (Mathew et al., 1998). HSF2 has relatively short half-life of 60-70 minutes.
Treatment of cells with proteosome inhibitors causes an increase in the levels of HSF2 as
well as activation of HSF2 DNA binding and transcriptional activities. This is in part due
to increases in levels of HSF2 expression and in part due to decreased HSF2 degradation
(Mathew et al., 1998). No evidence has been seen for HSF2 ubiquitination, but due to the
instability of ubiquitinated proteins, it can be difficult to observe them. Interestingly, the
drug MG132 which inhibits the proteosome activity and activates HSF2 also leads to
increased conjugation of SUMO-2/3 (Saitoh and Hinchey, 2000). Our data indicates that
HSF2 is also a substrate for SUMO-2 modification in vitro. Perhaps MG132 induces
SUMO-2/3 modification of HSF2 that is consequently resistant to protein degradation.
Protein stabilization by SUMO-1 modification has been observed for IκB as well as
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possibly for p53. This might suggest that SUMO has multiple functions with respect to
HSF2.
Answers to the above questions can lead to greater understanding of the functions
of HSF2 and SUMO-1 in the cell. They can also lead to broader questions concerning
the function of sub-domains and how the organization of nuclear activities leads to the
appropriate gene regulation and protein expression in cell specific and developmental
manners.

Appendix
APPENDIX A: LIST OF ABBREVIATIONS
HSF, heat shock factor
HSE, heat shock element
hsp, heat shock protein,
PML, promeylocytic leukemia protein
SUMO-1, small ubiquitin-like modifier-1
PCR, polymerase chain reaction
RT-PCR, reverse transcriptase couple PCR
DAPI, 4`,6-diamidino-2-phenylindole
PBS, phosphate buffered saline
BSA, bovine serum albumin
FBS, fetal bovine serum
SDS-PAGE, sodium dodecylsulfate polyacrylamide gel electrophoresis
MeOH, methanol
RanGAP1, Ran GTPase activating protein-1
kb, kilobase
nt, nucleotide
kDa, kilodalton
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